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The accumulation of irreparable cellular damage restricts healthspan after acute 
stress or natural aging. Senescent cells are thought to impair tissue function and 
their genetic clearance can delay features of aging. Identifying how senescent cells 
avoid apoptosis allows for the prospective design of anti-senescence compounds 
to address whether homeostasis can also be restored.
Here, we identify FOXO4 as a pivot in senescent cell viability. We designed 
a FOXO4 peptide which perturbs the FOXO4 interaction with p53. In senescent 
cells, this selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis. 
Under conditions where it was well tolerated in vivo, this FOXO4 peptide neutralized 
Doxorubicin-induced chemotoxicity. Moreover, it restored fitness, fur density and 
renal function in both fast aging XpdTTD/TTD and naturally aged mice. Thus, therapeutic 
targeting of senescent cells is feasible under conditions where loss of health has 
already occurred and in doing so tissue homeostasis can effectively be restored.
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Introduction
Unresolved DNA damage can impair cellular function, promote disease 
development and accelerate aging(Lopez-Otin et al., 2013). To prevent such 
undesired consequences, cells are equipped with a range of DNA repair mechanisms 
(Hoeijmakers, 2009). However, these mechanisms are not flawless. When repair 
falls short, tissue integrity is still at least initially maintained by independent stress-
response mechanisms as apoptosis and cellular senescence(de Keizer, 2017). 
Senescent cells are permanently withdrawn from the cell cycle and generally 
develop a persistent pro-inflammatory phenotype, called the Senescence-Associated 
Secretory Phenotype or SASP(Coppe et al., 2008). The SASP influences the cellular 
microenvironment, which can be beneficial early in life, or in an acute setting of wound 
healing(Demaria et al., 2014; Munoz-Espin et al., 2013). However, unlike apoptotic 
cells, which are permanently eliminated, senescent cells can prevail for prolonged 
periods of time and accumulate with age(Krishnamurthy et al., 2004). Because of 
their low, but chronic SASP, persistent senescent cells are thought to accelerate 
aging and the onset of age-related diseases(de Keizer, 2017). Indeed, senescence 
has been associated with a plethora of (age-related) pathologies and, conversely, 
genetic clearance of senescent cells can delay features of aging(Baker et al., 2016). 
It remains largely unclear how damaged cells avoid apoptosis in favor of senescence. 
We set out to address this question and to determine whether therapeutic targeting 
of senescent cells could not only delay, but also counteract the loss of tissue 
homeostasis after acute damaging medical treatments as chemotherapy, or chronic 
damage causer either by accelerated or natural aging.
Results
FOXO4 is elevated in senescent cells and maintains their viability
To identify potential pivots in senescent cell viability, we initiated this study by 
investigating whether apoptosis-related pathways are altered in senescent cells. We 
performed unbiased RNA sequencing on samples of genomically stable primary 
human IMR90 fibroblasts and IMR90 induced to senesce by Ionizing Radiation 
(Rodier et al., 2011). As senescent cells are reportedly apoptosis-resistant (Wang, 
1995), we expected pro-apoptotic genes to be repressed. Surprisingly, however, 
senescent IMR90 showed an upregulation of prominent pro-apoptotic “initiators” 
PUMA and BIM while the anti-apoptotic “guardian” BCL-2 was reduced (Fig. 1A + S1A). 
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Fig. 1: FOXO4 is elevated in senescent normal fibroblasts and ensures their viability
A) Schematic representation of the mRNA expression changes (Fig. S1A) of the cell-intrinsic 
apoptosis pathway(Tait and Green, 2010) between senescent and control (proliferating) IMR90 
fibroblasts. Inset: Immunofluorescence for PUMA, BIM and BCL2. B) Volcano plot comparing 
transcriptional regulators in senescent vs. control IMR90. (See Fig. S1B for expression and 
p-values). Dark blue: associated with apoptosis. Inset, left: RNA expression of the FOXO cluster. 
N.D. Not detectable. Right: Protein levels of the FOXO cluster. FOXO1 was ectopically expressed 
as positive control. C) QPCR for changes in FOXO1, 3 and 4 mRNA after senescence-induction by 
10Gy IR. p21Cip1 (biphasic increase), p53 and ETS2 (biphasic decrease) are included as controls. 
D) Immunoblot for changes in FOXO3 and 4 protein levels after senescence-induction by 10Gy IR. 
E) The senescence-induced FOXO4 mRNA expression is successfully countered by two shRNAs. 
F) Cytochrome-C release assay (left) as measure for apoptosis in the conditions of E), quantified 
in a histogram (right). G) Induction of cleaved Caspase-3 after senescence induction in (mouse-
specific) FOXO4-deprived wildtype or bax/bak-/- BMK cells. H) AqueousOne viability (left) and 
colony density (right; see also Fig. S1C) of control and senescent IMR90 cells transduced with the 
short hairpins used in E).
Voorbereid document - Marjolein Baar.indd   34 17-04-19   17:20
35
Targeted apoptosis of senescent cells
This suggested senescent IMR90 are primed to undergo apoptosis, but that 
the execution of the death program is restrained. We reasoned such a brake could 
potentially be a transcriptional regulator and focused on transcription factors that have 
previously been linked to apoptosis, including STAT1, 2 and 4, RELB, NFκB, TP53 
and FOXO4 (Fig. 1B + S1B). Interference with JAK-STAT signaling in known not to 
affect the viability of senescent cells(Xu et al., 2015) and we have previously observed 
similar effects for NFκB and p53 inhibition(Freund et al., 2011; Rodier et al., 2009). 
Our interest was therefore directed to a factor that has not yet been studied as such, 
FOXO4 (Fig. 1B). FOXO4 belongs to a larger mammalian family, with FOXO1 and 
3 being its major siblings. FOXOs are well studied in aging and tissue homeostasis 
as targets of Insulin/IGF signaling and as regulators of Reactive Oxygen Species(de 
Keizer et al., 2011; Eijkelenboom and Burgering, 2013; Martins et al., 2016). Whereas 
senescence-inducing IR showed only mild effects on the expression of FOXO1 and 
3, both FOXO4 mRNA and protein expression progressively increased (Fig. 1C+D). 
We therefore wondered whether FOXO4 could function to balance senescence and 
apoptosis. We stably inhibited FOXO4 expression using lentiviral shRNA (Fig. 1E). 
FOXO4 inhibition prior to senescence-induction resulted in a release of mitochondrial 
Cytochrome C (Fig. 1F) and BAX/BAK-dependent Caspase-3 cleavage (Fig. 1G). In 
addition, FOXO4 inhibition in cells that were already senescent, but not their control 
counterparts, reduced viability and cell density (Fig. 1H +S1C). Together, this shows 
that after acute damage FOXO4 favors senescence over apoptosis and maintains 
viability of senescent cells by repressing their apoptosis response.
FOXO4-DRI disrupts PML/DNA-SCARS and releases active p53 in senescent cells
Interference with FOXO4 signaling could be a strategy to eliminate senescent 
cells and thereby potentially target senescence-related diseases. However, shRNA-
mediated repression of FOXO4 would be complicated to translate to the clinic. Thus, 
we decided to design compounds that could structurally interfere with FOXO4 function 
instead. Immunofluorescence experiments showed FOXO4 to be gradually recruited 
to euchromatin foci after senescence-induction (Fig. 2A-C+ S2A-D). As senescence 
develops, PML bodies fuse with 53BP1-containing DNA-SCARS to jointly regulate 
expression of the SASP(Rodier et al., 2011). High resolution Structured Illumination 
Microscopy (SIM) of nuclei of senescent cells showed FOXO4 to reside within these 
PML bodies, adjacent to 53BP1-containing DNA-SCARS (Fig. 2D; Mov.1+2; Fig. 
S2E-I).
2
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Fig. 2: FOXO4 localizes to senescence-associated PML/DNA-SCARS, which contain 
active p53 and can be disrupted by FOXO4-DRI
A) FOXO4 foci and Senescence-Associated Heterochromatin Structures in senescent IMR90 (See 
also Fig. S2A-I). Bottom: Intensity plot (arbitrary units) of individual pixels measured by the indicated 
line. B) Quantification of cells containing ≥3 FOXO4 foci in time after senescence-inducing IR. C) 
FOXO4 foci in senescent cells transduced with the shRNAs against FOXO4 described in 1E). D) 
Structured Illumination Microscopic (SIM) image of the nucleus of a senescent IMR90 cell stained 
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for FOXO4, 53BP1 and PML. Yellow arrow: Area processed for 3D surface-rendering (Insets). 
E) FOXO4 and Ser15-phosphorylated p53, assessed as in 2A. Note that for FOXO4 a different 
antibody (Sigma) was used. F+G) Sequence (H indicates predicted helix) and 3D structure of 
FOXO4 used for the design of FOXO4-DRI. The amino acids indicated in yellow in F) are shown as 
yellow spheres in the displayed structure of FOXO4 (3L2C, protein databank). Green aa in F) are 
not visualized in this 3D structure, but are part of the FOXO4-DRI sequence. Red aa in G) change 
most upon p53-interaction (Wang et al., 2008). See also Fig. S2J-L. H) 1H,15N HSQC NMR spectrum 
of 15N-labelled recombinant FOXO486-206 incubated with increasing stoichiometric equivalents of 
recombinant p53 (60, 120, 240 or 300 µM, respectively). I) Experiment as in H), but with 1x or 
2x stoichiometric equivalents of FOXO4-DRI (300 or 600 µM, respectively). J) Cellular uptake 
of FOXO4-DRI in senescent IMR90 visualized by an antibody against the HIV-TAT sequence. K) 
Quantification of the number of FOXO4/PML/53BP1-DNA-SCARS in control and senescent IMR90 
incubated 3d with 25μM FOXO4-DRI and the pan Caspase-inhibitor QVD-OPH. # of small 53BP1 
foci shown as control. Only infrequently FOXO4 foci were visible in control cells. L) Schematic 
representation of the p21CIp1 (CDKN1a) promoter in which the canonical FOXO target sequence is 
flanked by two p53 binding sites. M+N) Quantification of nuclear p21Cip1 intensity of senescent IMR90 
treated as in K). N) Left: Immunoblot of senescent IMR90 cells incubated for the indicated time 
points with FOXO4-DRI and processed for Ser15-phosphorylated and total p53. Middle: Nuclear 
exclusion of pSer15-p53 in cell treated as in K+M). Right: Quantification of pSer15-p53 foci per 
nucleus of senescent IMR90.
p53 controls both apoptosis and senescence(Kruiswijk et al., 2015) and localizes 
to DNA-SCARS in senescent cells(Rodier et al., 2011). Under those conditions 
p53 is phosphorylated by ATM on Ser15, which blocks its MDM2-mediated 
degradation(Rodier et al., 2009). Consistent with the observation of FOXO4 residing 
in PML bodies, FOXO4 localized next to phosphorylated ATM substrates (Fig. S2I) 
and pS15-phosphorylated p53 (Fig. 2E). This raised the question whether FOXO4 
could maintain senescent cell viability by binding p53 and inhibiting p53-mediated 
apoptosis in favor of cell cycle arrest.
FOXOs can interact with p53, and the interaction domain has been characterized 
by NMR (Wang et al., 2008). To interfere with the FOXO4-p53 interaction, we 
therefore designed a cell-permeable peptide comprising part of the p53-interaction 
domain in FOXO4 (Fig. 2F+G). FOXO1 and FOXO3 are essential to numerous 
endogenous processes as development, differentiation and tumor suppression, roles 
not prominently attributed to FOXO4(Hosaka et al., 2004; Nakae et al., 2003; Paik et 
al., 2007; Renault et al., 2009). Another difference with FOXO1 and 3 is that FOXO4 
is only marginally expressed in most tissues (Fig. S2J+K) and FOXO4 knockout 
mice do not show a striking phenotype (Hosaka et al., 2004; Paik et al., 2007). We 
therefore chose a region in FOXO4 that is conserved in both humans and mice, but 
differs from FOXO1 and FOXO3 (Fig. S2L).
Research on peptide chemistry has shown that protein domains containing 
natural L-peptides can sometimes be mimicked by using D-amino acids in a retro-
reversed sequence (Guichard et al., 1994). Modification of peptides to such a D-Retro 
Inverso (DRI)-isoform can render peptides new chemical properties, which may 
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improve their potency in vitro and in vivo (Borsello et al., 2003). Several DRI-modified 
peptides have been shown to be well tolerated and therapeutically effective in clinical 
trials. These include a double blinded, randomized, placebo-controlled Phase IIb 
trial(Beydoun et al., 2015; Deloche et al., 2014; Suckfuell et al., 2014) and a Phase I 
trial for systemic treatment of solid tumors(Warso et al., 2013), together showing there 
is precedence for DRI peptides in clinical therapy. This provided the rationale for 
designing the FOXO4 peptide in a DRI conformation, henceforth named FOXO4-DRI. 
We performed competition experiments by NMR to investigate whether FOXO4-DRI 
can inhibit the interaction between p53 and FOXO4 in vitro. Titration of a recombinant 
N-terminal domain of p53 (aa1-312) to a solution containing the 1H, 15N-labelled 
FOXO4 Forkhead (FH) Domain (aa486-206) induced a progressive chemical shift 
perturbation (CSPs) of 1H, 15N HSQC cross peaks, indicating specific binding of p53 
to FOXO4 (Fig. 2H). Stepwise addition of the FOXO4-DRI peptide to this complex 
caused the CSPs of FOXO4 to be reverted back to the unbound state, indicating 
FOXO4-DRI competes with FOXO4 for p53 binding in a dose-dependent manner 
and doing so with higher affinity (Fig. 2I).
To facilitate cellular uptake of FOXO4-DRI, it was designed as a fusion with HIV-
TAT, a basic and hydrophilic sequence which allows energy-independent cellular 
uptake of cargo through transient pore formation (Herce and Garcia, 2007). Using an 
antibody against HIV-TAT, we observed FOXO4-DRI to be taken up as soon as 2-4h 
after administration and to remain detectable for at least 72h (Fig. 2J). Given that the 
affinity of antibodies is generally low, this indicates FOXO4-DRI effectively enters 
senescent cells at high intracellular concentrations, which remain abundant and 
stable over a prolonged period of time. Following its uptake, FOXO4-DRI reduced the 
number of senescence-induced FOXO4 foci, PML bodies and 53BP1 DNA-SCARS, 
while not affecting the number of small 53BP1 foci (Fig. 2K).
FOXO4 can regulate expression of the p53-target p21cip1 in senescent cells (de 
Keizer et al., 2010) and through p21cip1, p53 can induce p16in4a-independent cell cycle 
arrest in senescent cells(Di et al., 1994). Moreover, p53 can induce apoptosis either 
through transactivating pro-apoptosis genes, but also in a transcription-independent 
manner by translocating to the mitochondria (Mihara et al., 2003). Examination of 
the promoter of Cdkn1a, the gene encoding p21Cip1, showed a canonical FOXO 
target sequence to be flanked by two p53 binding sites (Fig. 2L). We therefore 
investigated the effect of FOXO4-DRI on p21Cip1 and p53. FOXO4-DRI reduced 
senescence-associated p21Cip1 levels (Fig. L) and promoted the accumulation and 
nuclear exclusion of active pSer15-p53 (Fig. 2M + S2M). Together, these results 
show that by competing with endogenous FOXO4 for p53 binding, FOXO4-DRI 
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disrupts senescence-associated FOXO4/PML/DNA-SCARS and causes nuclear 
exclusion of active p53.
FOXO4-DRI can selectively and potently target senescent cells for p53- 
dependent apoptosis
Given the reported pro-apoptotic role of active p53 when recruited to mitochondria, 
we next assessed the effects on senescent cell viability. Incubation of senescent and 
control IMR90 with increasing concentrations of FOXO4-DRI showed FOXO4-DRI 
to potently and selectively (11.73 fold difference) reduce the viability of senescent 
vs. control IMR90 (Fig. 3A) and other normal cells (Fig. S3A). Real-time cell density 
measurements revealed the effect to occur as soon as 24-36 hours after administration 
(Fig. 3B). Neither the same peptide in L-isoform (Fig. 3C), nor an unrelated DRI-
peptide based on a distinct Forkhead protein, FOXM1 (Kruiswijk et al., 2016), affected 
senescent cell viability (Fig. 3D). These results show that FOXO4-DRI can target 
senescent cells and highlight the importance of the DRI-modification for its potency.
Two classes of anti-senescence compounds have been reported so far: Quercetin/
Dasatinib, either alone or in combination(Zhu et al., 2015), and the pan-BCL inhibitors 
ABT-263/737(Chang et al., 2016; Yosef et al., 2016). Quercetin and Dasatinib have 
been reported to be non-specific(Chang et al., 2016). We found no selectivity towards 
senescent IMR90 (Fig. S3B), and therefore this cocktail was not explored further. 
ABT-263 (Chang et al., 2016) and ABT-737 (Yosef et al., 2016) target the BCL-2/W/
XL family of anti-apoptotic guardians (See also Fig. 1A). Indeed, ABT-737 showed 
selectivity for senescent IMR90 (Fig. S3B). However, already at low doses it appeared 
to influence control cells as well (Fig. S3B). Also in a treatment regimen where both 
compounds were added in consecutive rounds of lower concentrations FOXO4-DRI 
proved to be selective against senescence yet safe to normal cells (Fig. 3E + S3C).
We next addressed the role of p53 in FOXO4-DRI-mediated clearance of 
senescent cells. Stable knock-down of p53 reduced the ability of FOXO4-DRI to 
target senescent IMR90 (Fig. 3F + S3D). A similar effect was observed when the 
senescent cells were co-incubated with the pan-caspase inhibitors QVD-OPH or 
ZVAD-FMK (Fig. 3G), suggesting a Caspase-dependent effect. Indeed, real-time 
imaging in the presence of a Caspase-3/7-activatable dye showed FOXO4-DRI to 
specifically induce Caspase-3/7 activation in senescent, but not control, cells (Fig. 
3H + Mov. 3+4). Together, these data show that FOXO4-DRI potently and selectively 
reduces the viability of senescent cells by competing with FOXO4-p53 binding, 
thereby triggering release of active p53 to the cytosol and inducing cell-intrinsic 
apoptosis through Caspase-3/7. This establishes FOXO4-DRI as a genuine inducer 
of TASC: Targeted Apoptosis of Senescent Cells.
2
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Fig. 3: FOXO4-DRI selectively eliminates senescent cells through p53-mediated 
cell-intrinsic apoptosis
A) Viability assay of senescent and control IMR90 incubated with increasing doses of FOXO4-DRI 
(μM). The selectivity index (SI50) reflects the differences in EC50 of a non-regression analysis 
for both groups. See also Fig. S3A. B) Real-time cell density measurement by xCELLigence of 
control and senescent IMR90 incubated with or without FOXO4-DRI (25μM). C) Viability assay 
comparing the effects of increasing doses of FOXO4-DRI and the same peptide in L-isoform, 
FOXO4-L. D) Viability assay comparing FOXO4-DRI, FOXO4-L, and an unrelated FOXM1-DRI 
peptide(Kruiswijk et al., 2016), at 6.25, 12.5 and 25μM, respectively. E) Viability assay comparing 
the pan-BCL inhibitor ABT-737 to FOXO4-DRI, when applied in three consecutive rounds at 1/3 
the final concentration each (See also Fig. S3B+C). SI75 reflects differences in EC75 of a non-
regression analysis for both groups. F) Viability assay comparing the effect of FOXO4-DRI on 
cells depleted for p53 by shRNA. See Fig. S3D for effects on p53 expression. G) Viability assay 
comparing the effect of FOXO4-DRI senescent cells incubated with pan-caspase inhibitors (20μM). 
H) Representative still images of real-time confocal-based imaging of senescent and control cells 
in the presence of a Caspase-3/7 activatable dye (green) and incubated with FOXO4-DRI. See 
also Mov. 3+4. Imaging started 8h after FOXO4-DRI addition.
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FOXO4-DRI counteracts chemotherapy-induced senescence and loss of liver 
function
Given the potency of FOXO4-DRI against senescence in vitro, we wondered 
whether FOXO4-DRI could be of therapeutic use against senescence-related 
pathologies. We therefore employed three independent in vivo senescence-models, 
one for chemotoxicity (Fig. 4), one for accelerated aging (Fig. 5+6) and one for natural 
aging (Fig. 7). In all of these, we made use of the recently developed senescence-
detection system: p16::3MR. In this system, the promoter of the major senescence 
gene p16ink4a drives expression of Renilla Luciferase (RLUC) to allow longitudinal 
visualization of senescence. In addition, it expresses a Thymidine Kinase from the 
Herpes Simplex virus, which induces apoptosis when cells are presented with its 
substrate Ganciclovir (Fig. S4A and(Demaria et al., 2014)).
Off-target toxicity limits the maximum tolerated dose of chemotherapeutic drugs 
and causes long term health problems in cancer survivors, including an acceleration 
of aging (Henderson et al., 2014). Chemotherapy can induce senescence (Ewald et al., 
2010), and we therefore determined whether therapeutic removal of senescence could 
influence chemotoxicity. As an example, we used the common chemotherapeutic 
drug Doxorubicin, which can indeed induce senescence (Cahu et al., 2012; Roninson, 
2003) and liver toxicity in rodents and humans(Damodar et al., 2014). In agreement 
with these reports, Doxorubicin induced senescence in IMR90 in vitro, evident by 
elevated SA-β-GAL activity, expression of p16ink4a, and the early and late SASP 
factors IL-1α and IL-6 (Orjalo et al., 2009), respectively (Fig. 4A-C; S4B). As seen 
for IR-senescent cells (Fig. 2+3), Doxorubicin-induced senescent cells showed an 
upregulation in FOXO4 foci (Fig.4B+C) and FOXO4-DRI potently and selectively 
lowered the viability of Doxorubicin-senescent vs. control IMR90 (Fig. 4D). In line 
with the IR-senescence data, low effective doses of FOXO4-DRI were well tolerated 
in normal IMR90 compared to ABT-737, while being very potent against Doxorubicin-
senescent cells at higher doses (Fig. 4E). Also in this setting, the potency of FOXO4-
DRI was more pronounced when applied in consecutive rounds (Fig. 4F + S4C).
It could be that FOXO4-DRI merely lowers the threshold for cells to enter 
apoptosis after DNA damage. This would impair its potential for in vivo or clinical 
translation. Incubation of normal IMR90 with FOXO4-DRI, administered at various 
time-points prior to Doxorubicin-exposure, did not influence the sensitivity of cells 
to Doxorubicin (Fig. 4G). In contrast, Doxorubicin-senescent cells were effectively 
cleared. Thus, FOXO4-DRI does not predispose healthy cells to DNA-damage, but 
selectively targets cells that have undergone senescence as a consequence of 
earlier Doxorubicin-exposure. Together this prompted us to try a similar sequential 
treatment regimen of FOXO4-DRI in Doxorubicin-exposed mice in vivo.
2
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Fig. 4: FOXO4-DRI counteracts Doxorubicin-induced senescence and chemotoxicity 
in vivo
A) SA-β-GAL assay to detect senescence in IMR90 7d after 2x treatment (1d in between) with 
0.1μM Doxorubicin. B) Immunofluorescence for p16ink4a and FOXO4 in control or Doxo-senescent 
IMR90. See also Fig. S4B. C) Quantification of the % of cells positive for p16ink4a, IL1α, IL6 and 
FOXO4 foci after Doxorubicin-induced senescence. D) Viability assay comparing the effect of 
FOXO4-DRI on control and Doxo-senescent cells in vitro. SI determined as in Fig. 3A. E) Viability 
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assay comparing ABT-737 vs. FOXO4-DRI on Doxo-senescent cells. F) Same as in E, but both 
added 3x at 1/3 the final concentration. See also Fig. S4C. G) Viability assay comparing effects of 
incubation of FOXO4-DRI for various time points prior, during or after Doxorubicin exposure (blue 
line) vs. cells already induced to senesce by Doxorubicin (green boxes). M=Mock. H) Representative 
bioluminescence image and quantification of p16-driven senescence (RLUC) in p16::3MR mice (See 
Fig. S4A+D), treated as indicated with Doxorubicin, followed by FOXO4-DRI or Mock. I) Timeline 
of experiments in J-N. Doxorubicin: 2x i.p. at 10mg/kg. FOXO4-DRI: 3x i.v. at 5mg/kg, every other 
day (day 1, 3 and 5). J) Quantification of the % change in body weight of Doxorubicin-exposed mice 
treated with FOXO4-DRI or PBS, respectively. K) Quantification of the number of liver cells with ≥ 
10 FOXO4 foci after Doxorubicin-exposure and treatment with PBS or FOXO4-DRI. L) Visualization 
and quantification of the % of liver cells from the mice in (K) expressing IL-6. M) Quantification of the 
Doxorubicin-induced increase in plasma AST levels as marker for liver damage. N) Quantification 
of the effects of PBS or FOXO4-DRI on Doxorubicin-induced plasma levels of AST and Urea as 
markers for liver and kidney damage, respectively. See also Fig. S4E+F.
In follow-up of the in vitro data, Doxorubicin progressively induced senescence in 
vivo as detected by p16ink4a-driven RLUC in p16::3MR mice (Fig. S4D). Furthermore, 
as seen in patients, Doxorubicin reduced total body weight (Fig. 4J) and induced 
expression of FOXO4 foci and IL-6 in the liver (Fig. 4K+L). Strikingly, these effects 
were neutralized after sequential treatment with FOXO4-DRI (Fig. H-L). We 
therefore wondered whether liver function was also affected. Doxorubicin strongly 
induce plasma levels of Aspartate Aminotransferase, AST, an established indicator 
of liver damage(Damodar et al., 2014)(Fig. 4M). Excitingly, FOXO4-DRI potently 
counteracted the Doxorubicin-induced increase in plasma AST (Fig. 4N). To address 
whether these effects are mediated through clearance of senescence, we combined 
treatment of FOXO4-DRI with GCV, to facilitate senescence clearance through the 
TK suicide gene of p16::3MR construct. GCV reduced Doxorubicin-induced p16-
RLUC expression (Fig. S4E) and plasma AST levels (Fig. 4M + S4F), indicating 
AST reduction is indeed caused by clearance of senescent cells. In both cases, 
FOXO4-DRI did not further enhance these effects. Together, these data indicate 
that FOXO4-DRI is effective in reducing Doxorubicin-induced senescence in vitro 
and in vivo and in doing so neutralizes the Doxorubicin-induced loss in body weight 
and liver toxicity. Thus, FOXO4-DRI is effective against chemotoxicity.
FOXO4-DRI counteracts senescence and features of frailty in fast aging 
XpdTTD/TTD mice
We next wondered whether FOXO4-DRI could influence the healthspan of mice 
in which senescence and the concomitant loss of tissue homeostasis were not 
actively induced, but were allowed to develop spontaneously as a consequence of 
aging. As is the case for humans(Ferrucci et al., 2005), we expected strong biological 
variation in senescence and the SASP in naturally aged wildtype mice. To reduce 
the effects of biological noise, we therefore decided to first employ fast aging mice. 
We sought a model that recapitulates features of natural aging and does not suffer 
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from age-related pathologies caused by other processes as apoptosis(de Keizer, 
2017). This we found in XpdTTD/TTD, a model based on the human premature aging 
syndrome Trichothiodystrophy (TTD)(de Boer et al., 2002; de Boer et al., 1998). 
Using the p16::3MR reporter system, we observed that already at young age XpdTTD/
TTD animals show high levels of p16-positive senescence (Fig. 5A). As also seen for 
Doxorubicin-induced senescence, FOXO4-DRI reduced this effect (Fig. 5B), arguing 
that XpdTTD/TTD is a valid fast aging model for studying the effects of FOXO4-DRI on 
spontaneously developed senescence in vivo.
Underscoring their aging phenotype, XpdTTD/TTD mice show accelerated loss of 
hair (Fig. 5D and (de Boer et al., 1998)). While not initially focused on this phenotype, 
we observed a robust improvement of fur density in FOXO4-DRI treated XpdTTD/
TTD mice (Fig. 5C+D and S5A). To address this more quantitatively, we determined 
the infrared-measured abdominal surface temperature of the mice. Due to the lack 
of fur, the abdominal temperature of XpdTTD/TTD mice was several degrees higher 
than wildtype counterparts, an effect reduced by FOXO4-DRI (Fig. 5E). A second 
unexpected observation was found in the behavior of the treated mice. Whereas 
XpdTTD/TTD mice generally show less exploratory behavior compared to wildtype 
littermates, FOXO4-DRI treated animals were noticeably more active (Fig. S5B). 
To also investigate this more quantitatively, we scored the responsiveness of the 
mice to gentle physical stimuli. Despite individual variation, XpdTTD/TTD mice were on 
average considerably more responsive to such stimuli after FOXO4-DRI treatment 
(Fig. 5F). Finally, as a more objective measure of activity, we tracked voluntary 
physical activity in a set-up in which the mice were continuously housed in cages 
with free access to running wheels. Despite significant individual differences, XpdTTD/
TTD mice were found to run 1.37 ± 0.54 km/day on average, compared to 9.37 ± 1.1 
km/day seen for wildtype mice, arguing they are indeed less mobile (Fig. 5G). In line 
with the behavioral results, exposure of the mice to FOXO4-DRI increased running 
wheel activity over time in the majority of these (Fig.H+I). Together, these results 
indicate that FOXO4-DRI can reduce cellular senescence and counteract hair loss 
and general frailty in fast aging XpdTTD/TTD mice.
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Fig. 5: FOXO4-DRI decreases senescence and counters features of frailty in fast 
aging XpdTTD/TTD mice
A) Representative mice and quantification of p16ink4a-driven RLUC Radiance in 26wk young wildtype 
and XpdTTD/TTD mice crossed into p16::3MR. B) Left: Timeline for visualization of effects of FOXO4-
DRI or PBS on p16-driven senescence by bioluminescence in XpdTTD/TTD. Middle: Representative 
visualization of p16ink4a-driven senescence in the same XpdTTD/TTD-p16::3MR mouse before and after 
FOXO4-DRI. Right: Quantification of the effects of FOXO4-DRI or PBS on senescence in a larger 
cohort of XpdTTD/TTD-p16::3MR mice. C) Timeline for measuring the effects of FOXO4-DRI or PBS on 
hair density, behavior and running wheel activity in D-I. D) FOXO4-DRI improves fur appearance of 
XpdTTD/TTD mice. Left panels: Representative images of the same XpdTTD/TTD animal before and after 
treatment with FOXO4-DRI. Right panel: quantification of the average change in fur score (See 
also Fig. S5A). E) Quantification of abdominal temperature measured by infrared thermometer as 
measure for fur density of wt vs. XpdTTD/TTD mice (left) and the effects of FOXO4-DRI and PBS in 
the mice from D and Fig. S5A (right). F) Quantification of the response of the XpdTTD/TTD mice from D 
to gentle physical stimuli before and after treatment with FOXO4-DRI or PBS. Note that XpdTTD/TTD 
mice are generally relatively non-responsive. See also Fig. S5B. G) Quantification of the average 
distance run per day of wt. vs XpdTTD/TTD. H) Example of changes in running wheel behavior of a 
wt vs. XpdTTD/TTD mouse treated with FOXO4-DRI. Data normalized to 100% for respective running 
wheel activity at baseline. On day 10 a blood sample was taken, resulting in a transient decrease 
in activity. I) Quantification of the average change in running wheel activity in wildtype and XpdTTD/
TTD mice after PBS or FOXO4-RI treatment.
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FOXO4-DRI counteracts loss of renal function in fast aging XpdTTD/TTD mice
The phenotypical and behavioral results described above are difficult to connect 
to a molecular mechanism. We therefore decided to focus on the role of senescence 
in aging-induced decline in function of specific tissues. Pilot measurements of 
various metabolites in plasma samples of XpdTTD/TTD mice suggested they suffer from 
decreased renal function. As injected compounds tend to accumulate in the kidney, this 
together argued for investigating the potential of therapeutic removal of senescence in 
this organ. Urea is secreted through urine, but becomes detectable in the blood when 
glomerular filtration rates drop. Plasma Urea is therefore a marker of declined renal 
filtering capacity(Gowda et al., 2010; Lyman, 1986). In fact, it was recently established 
that semigenetic clearance of senescence can delay the aging-induced increase in 
plasma Urea, establishing senescence as a culprit for loss of renal filtering capacity 
during aging (Baker et al., 2016). As evident from the increase in plasma Urea levels, 
renal function indeed declines in wildtype mice as they age (Fig.6A; 26w vs. 130w). 
This was faithfully recapitulated early in life in XpdTTD/TTD (Fig. 6A; 26w WT vs 26w 
TTD). Both naturally aged wildtype and young XpdTTD/TTD kidneys showed a strong 
increase SA-β-GAL activity and IL-6 expression in the tubular regions (Fig. 6B+C). In 
addition, they also showed a significant increase in tubular cells positive for FOXO4 foci 
(Fig. 6D), together indicating that both modes show elevated senescence. Using an ex 
vivo system of aged kidney slices FOXO4-DRI induced strong TUNEL positivity within 
3 days (Fig. 6E and S6A-D), indicating that FOXO4-DRI can also induce apoptosis in 
these cells. Altogether this provided rationale for investigating the potency of FOXO4-
DRI on tubular senescence and renal function in in vivo.
A limitation to the therapeutic potential of the senolytic pan-BCL inhibitors ABT-
263/ABT-737 is their tendency to cause severe thrombocytopenia(Schoenwaelder 
et al., 2011). This is undesirable when actually aiming to restore healthspan of aged 
individuals. Comparing platelet levels before and 30d after treatment showed FOXO4-
DRI not to noticeably influence platelet levels (Fig. 6F) or other whole blood values 
(Fig. S6E). Neither did it cause deleterious effects on non-proliferative tissues as 
far as tested, e.g. the heart (Fig. S6F). Encouraged by the passing of at last these 
initial safety concerns, we progressed to measuring the effects of FOXO4-DRI on 
renal senescence and functional capacity. In line with the SA-β-GAL data, tubuli of 
XpdTTD/TTD kidneys show severe loss of LMNB1 (Fig. 6G), a robust molecular marker 
of senescence (Freund et al., 2012). This is paralleled with elevated IL-6 (e.g. Fig. 
6J), indicative of SASP, and elevated Urea levels in the blood (e.g. Fig. 6K). SASP 
factors as IL-6 may be the cause for the observed loss in renal function and we 
wondered how FOXO4-DRI would function under such high-SASP conditions. In vitro 
experiments showed FOXO4-DRI to be more potent against senescent cells in which 
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SASP was transiently boosted by recombinant IL1α/β or LPS, whereas an IL1 receptor 
antagonist or the general anti-inflammatory drug Cortisol reduced its potency (Fig. 
6H+I). Thus, FOXO4-DRI actually is most effective against senescent cells expressing 
high levels of SASP and could as such be particularly effective against loss of renal 
function. Excitingly, while not substantially influencing total body nor kidney weight 
(Fig. S6G), FOXO4-DRI treatment normalized the percentage of tubular cells lacking 
LMNB1 (Fig. 6G), the tubular IL-6 elevation (Fig. 6J) and the elevations in plasma 
Urea levels (Fig. 6K). To address whether this is mediated by senescence-clearance, 
we again made use of the ability of the 3MR construct to eliminate senescent cells 
through GCV. As GCV is typically administered i.p, we treated a cohort of XpdTTD/
TTD-p16::3MR mice i.p. with FOXO4-DRI and GCV. GVC and FOXO4-DRI induced a 
comparable reduction in plasma [Urea] in both groups (Fig. 6L). Thus, FOXO4-DRI 
targets high SASP-expressing senescent cells that have naturally developed in the 
kidneys of fast aging XpdTTD/TTD mice and in doing so restores kidney homeostasis.
FOXO4-DRI counteracts frailty and loss of renal function in naturally aged mice
Encouraged by these results, we decided to challenge whether FOXO4-DRI could 
also target senescence and tissue homeostasis in normal mice that were allowed to 
age naturally. As expected, the biological variation in p16-driven senescence was 
substantial in aged p16::3MR, compared to young XpdTTD/TTD-p16::3MR (Fig. 7A, 
and C). The variation in running wheel activity was too large to perform meaningful 
experiments (Fig. S7A). Nonetheless, while again not influencing platelet levels (Fig. 
7B), FOXO4-DRI significantly reduced p16-driven RLUC (Fig 7C), and could improve 
fur density (Fig. 7D) and responsiveness (Fig. 7E). Furthermore, in the kidneys of 
these mice FOXO4-DRI increased the number of LMNB1 positive cells (Fig. 7F), 
reduced IL-6 expression (Fig. 7G) and restored renal filtering capacity measured by 
decreased plasma Urea (Fig. 7H). As an extra control, also the plasma levels of a 
second metabolite indicative of reduced renal function, Creatinine, was measured. 
Also this was reduced by FOXO4-DRI, independently confirming the beneficial effect 
of FOXO4-DRI on the restoration of renal filtering capacity in naturally aged mice 
(Fig. 7I). As seen for the XpdTTD/TTD-p16::3MR mice, i.p administration of FOXO4-DRI 
or GCV equally reduced plasma Urea and Creatinine levels (Fig. 7J). Thus, senescent 
cells are causal for the reduction in renal function in fast aging XpdTTD/TTD and naturally 
aged wildtype mice and by selective targeting of high-SASP expressing senescent 
cells in the tubuli, FOXO4-DRI can restore kidney homeostasis. By inducing TASC, 
FOXO4-DRI may thus be a potent drug to restore loss of health after natural aging 
and is an attractive option to explore further in the battle against those age-related 
diseases that are at least in part driven by senescence.
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Fig. 6: By targeting senescence, FOXO4-DRI counters loss of renal function of 
XpdTTD/TTD mice
A) Quantification of renal filtering capacity measured by plasma [Urea] in 13, 26 and 130w old 
wildtype mice and 13 and 26w XpdTTD/TTD mice. B-D) Visualization of senescence (SA-β-GAL), the 
major SASP factor IL-6 and FOXO4 foci in 26w + 130w wildtype and 26w XpdTTD/TTD old kidneys. 
Tubuli (T), Glomeruli (G). Inset C): Magnification of SA-β-GAL to reveal affected areas. Inset 
D) quantification of the % of renal cells expressing ≥10 FOXO4 foci. E) TUNEL assay to detect 
apoptosis in kidney sections of 130w old wt mice treated 3d with PBS or FOXO4-DRI. See Fig. 
S6A-D for pipeline and results with shFOXO4. F) Quantification of the % of platelets at time of 
sacrifice vs. baseline for wt and XpdTTD/TTD mice treated with PBS or FOXO4-DRI. See also Fig. 
S6E. G) Representative Images of kidneys from 26w wt or XpdTTD/TTD mice stained for LMNB1 loss. 
Quantified are the average number of nuclei per kidney positive for LMNB1 (at least 400nuclei per 
mouse). H) Viability assay on control or senescent IMR90 incubated with recombinant IL1α, IL1β 
or IL1 receptor antagonist (IL1-RA) 24h prior to exposure of FOXO4-DRI. I) Viability plot showing 
the effect of FOXO4-DRI on control and senescent IMR90 pretreated with Cortisol and LPS, prior 
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to FOXO4-DRI treatment. J) Staining as in G), but for the SASP marker IL-6. Quantified is the 
average IL-6 intensity per kidney over at least 3 frames per mouse for at least 4 mice per group. K) 
Quantification of the % plasma [Urea] of three pooled cohorts of wt and XpdTTD/TTD mice (n=7-8 mice/
treatment) after 30d treatment with PBS or FOXO4-DRI. Data are represented as mean +/- SEM. 
See also Fig. S4G. L) Experiment as in K), but using Ganciclovir (GCV) to mediate semigenetic 
clearance of senescent cells through the Thymidine Kinase expressed by the p16::3MR construct. 
As GCV is i.p. administered, also FOXO4-DRI was i.p. administered in this experiment.
Fig. 7: By targeting senescence, FOXO4-DRI counters frailty and loss of renal 
function in naturally aged p16::3MR mice
A) Quantification of p16ink4a-driven RLUC radiance in 104w old p13::3MR mice compared to 26w 
counterparts. Note there is a larger degree of spread in the signal, suggesting biological variation. 
B) Quantification of the % platelets at time of sacrifice/baseline of naturally aged p16::3MR mice 
treated with PBS or FOXO4-DRI for 30d. Procedure as in Fig. 5C. C) Representative images and 
quantification of p16ink4a-driven RLUC radiance of mice the from B). D) Example of fur density in 
FOXO4-DRI vs. Mock-treated male p16::3MR mice. See also Fig. S7B. E) Quantification of the 
responsiveness of the mice in B-D treated with FOXO4-DRI or PBS. Analysis as in Fig. 5F. F-I) 
Quantification of the effects of FOXO4-DRI on LMNB1 loss and IL6 intensity in the kidneys and 
plasma [Urea] and [Creatinine] of the naturally aged p16::3MR mice from B). G) Quantification of % 
plasma [Urea] and [Creatinine] of naturally aged (110+wk) p16::3MR mice at 30d after i.p. injection 
with 3x 5mg/kg (every other day) FOXO4-DRI or 5x25mg/kg/day with GCV to clear senescent cells 
semigenetically.
2




With life expectancy projected to increase in the foreseeable future (Vaupel, 
2010) it is important to develop strategies to extend and restore healthspan. Cell-
penetrating peptides are relatively understudied in aging research. Further analysis 
of their use is warranted, as they serve several major advantages. Counter to 
broad-range inhibitors, CPPs can in theory target any surface-exposed stretch of 
amino acids to block specific protein-protein interactions and, in doing so, they can 
selectively modulate very specific downstream signaling events (Discussed in (de 
Keizer, 2017)). Other compounds, classified as senolytics, have been described to 
influence senescent cell viability. As a CPP, FOXO4-DRI differs from these by being 
designed around a specific amino acid sequence in a molecular target only mildly 
expressed in most normal tissues (see e.g. Fig. S2J+K). Though a more thorough 
analysis is required, as least as far as tested here FOXO4-DRI appears to be well 
tolerated, which is an absolutely critical milestone to pass when aiming to treat 
relatively healthy aged individuals(de Keizer, 2017).
FOXO4-DRI effectively disrupts the p53-FOXO4 interaction (Fig. 2H+I), but the 
importance of the FOXO4 protein itself is more complicated in DNA damage and 
senescence. As FOXO4-DRI causes nuclear exclusion of active p53, the levels of 
p21Cip1 decline (Fig. 2L-N). However, the loss of p21Cip1 alone is insufficient to induce 
apoptosis and was actually shown to induce a senescence-escape instead (Brown et 
al., 1997). Rather, the exclusion of p53 itself has been reported to induce apoptosis 
directly when located to mitochondria (Mihara et al., 2003), thereby explaining the 
FOXO4-DRI effects. FOXO4 shRNAs induce apoptosis in senescent IMR90 (Fig. 
1E-H), arguing that full FOXO4 inhibition might also be of use against senescence. 
True as this may be, chronic FOXO4 reduction is not advisable as FOXOs play a role 
in DNA-damage repair and Foxo4-/- mice are susceptible to acute damage(Zhou 
et al., 2009). In contrast to loss of FOXO4, FOXO4-DRI does not sensitize healthy 
cells to acute DNA damage (Fig. 4G). Thus, while permanent FOXO4 inhibition is 
inapplicable, the fact that as a CPP it can block a specific protein-protein interaction 
make FOXO4-DRI selective, and thereby well-tolerated and effective.
Based on these positive effects, it is now possible to envision a point on the 
horizon where the disease indications are identified that could benefit most from 
FOXO4-DRI therapy. High SASP-secreting cells are likely to play a much larger 
role in disease development than more sterile senescent cells. Through SASP, 
senescent cells may permanently confer a state of stemness in neighboring cells and 
thereby impair tissue function and renewal, an effect which we recently described 
in the senescence-stem lock model for aging (de Keizer, 2017). FOXO4-DRI has a 
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strong preference for targeting high-SASP subpopulations of senescent cells, but 
it is unclear what causes heterogeneity in the SASP. It will be a major achievement 
to unravel those mechanisms and to steer these such that therapeutic targeting is 
most beneficial. In that sense, identification of senescence-driven pathologies that 
rely on SASP may help in optimizing candidates for therapy. XpdTTD/TTD is pleiotropic 
model for aging that can be effectively used as a basis for such research. It is a well-
established model for osteoarthritis, especially in cohorts of older age than we used 
here (52w) (Botter et al., 2011) and for the unhealthy loss in muscle (sarcopenia) and 
fat mass(Wijnhoven et al., 2005).
Last, it is relevant to note that independent of aging and age-related diseases, 
FOXO4-DRI may be of use against the progression, stemness and migration of 
malignant cancer. Given that SASP factors influence these(Campisi, 2013), it will be 
particularly interesting to determine whether FOXO4-DRI affects those p53-wt cancer 
cells that have adopted a more migratory and stem-like state due to reprogramming by 
chronic SASP exposure. In any case, the here reported beneficial effects of FOXO4-
DRI provide a wide range of possibilities for studying the potential of therapeutic 
removal of senescence against diseases for which few options are available.
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STAR Methods
Contact for reagent and resource sharing
Further information and requests for resources and reagents should be directed 
to and will be fulfilled by the Lead Contact, Peter L.J. de Keizer (p.dekeizer@
erasmusmc.nl). The following materials: XpdTTD/TTD mice; p16::3MR mice and the 
peptide FOXO4-DRI are subject to patent applications and may be shared with 
research organizations for research and educational purposes only under an MTA 
to be discussed in good faith with the recipient; such MTA may restrict recipient to 
make any modifications to these materials.
Experimental model and subject details
Mouse experiments
This study was performed in strict accordance with all applicable federal and 
institutional policies. The protocol was approved by the Dutch Animal Ethics Committee. 
All the mice used in this study were of a C57BL/6J background; either wildtype, XpdTTD/
TTD mutated, expressing p16::3MR, or a combination thereof. The individual strains 
were backcrossed at least 10 times prior to this study. For the combination XpdTTD/TTD 
x p16::3MR the F1 generation was used. The mice were used at the ages indicated 
in the figures, for Doxorubicin-experiments at 10-40wks of age, for XpdTTD/TTD vs. wt 
experiments at 26-60 wks of age and for naturally aged mice at 115-130wks of age. All 
mice were kept in group housing until the start of the experiment after which they were 
placed in individual cages containing free access to a running wheel. Both sexes were 
used throughout the study. Where feasible, littermates of the same sex were used. These 
were randomly assigned to experimental groups.
Cell culture
The following cell lines were used in this study: IMR90 and WI-38 human fetal lung 
fibroblasts (female), BJ human foreskin fibroblasts (male), NIH3T3 mouse fibroblasts, 
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wt and bax/bak-/- littermate Baby Mouse Kidney (BMK) cells, Human Embryonic 
Kidney (HEK) 293LTV. All cells were obtained from ATCC, except for wt and bax/
bak-/- BMK cells which were a kind gift of Dr. Eileen White and have previously 
been described(Degenhardt et al., 2002). All cells were maintained in high glucose 
Dulbecco’s Modified Eagle’s Medium (Lonza), supplemented with 10% Fetal Calf 
Serum, penicillin/streptomycin and 0.05% glutamine. IMR90, BJ, WI-38 cells were 
kept at 5% CO2, 3% O2 and used between 28-45 population doublings. The BMK cells 
were kept at 5% CO2, 3% O2. The NIH3T3 and HEK293LTV cells were maintained at 
5% CO2, ambient O2. All cell lines were regularly tested for mycoplasma contamination 
using MycoAlert™ Mycoplasma Detection Kit (Lonza) and by assessment of (lack 
of) DAPI-positive microvesicles under fluorescence microscope. For IR-induced 
senescence, cells were exposed to 10Gy X- or Gamma rays, and analyzed 10 days 
later or otherwise indicated; control (proliferating) cells were mock irradiated, meaning 
they were taken out of the incubator and carried to the irradiator where they were 
placed outside for the same period of time as the irradiated cells. Senescence was 
confirmed by SA-β-GAL assay(Dimri et al., 1995) and/or changes in morphology. For 
Doxorubicin-induced senescence, the cells were treated twice with 0.1μM Doxorubicin 
(Sigma) with a 2d interval and analyzed 7d later, or as otherwise indicated.
Kidney slice culture
For tissue slice experiments, mice were used for which approval was obtained 
from the Committee on the Ethics of Animal Experiments of the Erasmus MC, 
where possible as a left-over from other experiments. Freshly isolated kidneys 
were sectioned in 200μM thick slices using a Vibratome (Leica, Eindhoven, the 
Netherlands). The sections were cultured in Dulbecco’s modified eagle medium with 
10% FCS at 37 °C, 5% CO2 on a shaker (60 rpm). Following incubation with shRNA-
containing lentiviral particles, or FOXO4-DRI, as indicated, the slices were fixed for 
30min in formalin and stored at -80. Subsequently, they were subsectioned to 10μM 




Antibodies against the following proteins were used (See also Key Resource 
Table): Cell Signaling: FOXO1 (2880), FOXO4 (9472), Phospho-Ser15 p53 (9286), 
PUMA (4976), BIM (C3C5), Cleaved Caspase-3 (9661), Sigma: FOXO4 (HPA040232), 
Tubulin (clone B512; no: T5168), Abcam: BCL2 (Ab7972), IL6 (ab6672), Histone 
H3 (Ab1791-100), BD Transduction Laboratories: p21Cip1 (610234), BD Pharmigen: 
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Cytochrome C (556432), R&D systems: IL1α clone 4414, MAB200), human IL6 
(AF206NA), Upstate: 53BP1 (05-726), Millipore: FOXO1 (07-702), Santa Cruz: p16Ink4a 
(JC8; sc56330), PML (N19; sc9862), LMNB1 (M-20; sc-6217), Novacastra: mouse 
p53 (NCL-p53-CM55).
The following reagents were used: QVD-OPH (BD biosciences), ZVAD-FMK 
(SelleckChem), Rotenone (Sigma-Aldrich, St. Louis, MO, USA), Doxorubicin (Santa 
Cruz).
Lentivirus production and shRNAs
Lentiviruses were produced in an MLII-certified lab area, using the 3rd generation 
production system. In brief, HEK293LTV cells were transfected (Lipofectamine2000) 
with the packaging/envelope plasmids pRSV-Rev, pMDLg/pRRE and pMD2.G, in 
combination with a lentiviral transfer plasmid of choice. The next day, the media 
was refreshed. After 48h, the media was collected for transduction and stored 
at 4ºC until needed. The following shRNA constructs were used (See also Key 
Resources Table): shGFP, shFOXO4-1: TRCN0000039720, Mature sequence: 
CCAGCTTCAGTCAGCAGTTAT, shFOXO4-2: TRCN0000039721, Mature sequence: 
CGTCCACGAAGCAGTTCAAAT, shFOXO4(mouse): TRCN0000071560, Mature 
sequence: GATCTGGATCTTGATATGTAT, shp53-1: TRCN0000003753, Mature 
sequence: CGGCGCACAGAGGAAGAGAAT and shp53-2: TRCN0000003754, 
Mature sequence: TCAGACCTATGGAAACTACTT. For transient expression of 
FOXO1, we transfected cells with pBabe-Puro-FOXO1(de Keizer et al., 2010). For 
stable transduction of HRASG12V, we used pLENTI-Puro (670-1)-HRASG12V(Freund et 
al., 2012). The day after transduction, the cells were refreshed and 24h later placed 
on selection in media containing 0.5μg/ml puromycin. Three days later, the media 
was refreshed with media containing 1μg/ml puromycin in which they were kept 
throughout the assay. After 7d of selection, the cells were used in their respective 
assays. The shRNA-transduced cells were subsequently exposed to senescence-
inducing IR and processed for Cell viability after 6d. For assays on IMR90 cells that 
were already senescent, treatment occurred as indicated (Fig. S1C) and the cells 
were subsequently processed for cell viability or cell density.
FOXO4 D-Retro-Inverso peptide development
FOXO4-DRI consists of the following amino acid sequence in D-Isoform:
H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH. MW: 5358.2 It was 
manufactured by Pepscan (Lelystad, the Netherlands) at >95% purity and stored 
at -20°C in 1mg powder aliquots until used to avoid freeze-thawing artefacts. For in 
vitro experiments FOXO4-DRI was dissolved in PBS to generate a 2mM stock. For 
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in vivo use, FOXO4-DRI was dissolved in PBS to generate a 5mg/ml stock solution, 
which was kept on ice until injection. Before injection the solution was brought to 
room temperature.
Total RNA isolation and mRNA sequencing sample preparation
The total RNA isolation and sequencing library preparation from IR-induced 
senescent and proliferating IMR90 cells was performed as follows: total RNA was 
isolated using Qiazol Lysis Reagent (Qiagen) and purified with the miRNeasy kit 
(Qiagen). The integrity (scores >9.0) of the RNA was determined on the Agilent 
2100 Bioanalyzer (Agilent). Total RNA enrichment for sequencing poly(A) RNAs 
was performed with the TruSeq mRNA sample preparation kit (Illumina). 1µg of total 
RNA for each sample was used for poly(A) RNA selection using magnetic beads 
coated with poly-dT, followed by thermal fragmentation. The fragmented poly(A) 
RNA enriched samples were subjected to cDNA synthesis using Illumina TruSeq 
preparation kit. cDNA was synthesized by reverse transcriptase (Super-Script II) 
using poly-dT and random hexamer primers. The cDNA fragments were then blunt-
ended through an end-repair reaction, followed by dA-tailing. Subsequently, specific 
double-stranded bar-coded adapters were ligated and library amplification for 15 
cycles was performed. The pooled cDNA library consisted of equal concentration 
bar-coded samples. The pooled library was sequenced in one lane, 36 bp single read 
on the HiSeq2500 (Illumina). The analysis of the sequencing dataset was performed 
by Total RNA analysis pipeline (TRAP).
Total RNA analysis pipeline (TRAP)
Reads were aligned to the human hg19 reference genome using the NARWHAL 
automation software. Exonic reads were summed per transcript. A specific transcript 
was considered expressed, when a minimum number of reads, i.e. 5 reads per 
million, could be aligned to a transcript. Pathway analysis was performed with 
Ingenuity Pathway Analysis Software (IPA; Version build 242990).
Production and purification of recombinant proteins
The constructs corresponding to human FOXO4 (residues 86 – 206) and human 
p53 (residues 1 – 312), were purchased from Genscript in a pUC cloning vector. The 
DNA sequence was codon optimized for protein production in bacterial cells and 
flanked by NcoI and BamHI restriction sites. The coding region was cloned into a 
modified pETM-11 bacterial expression vector (EMBL Heidelberg) which was derived 
from a pET-24d(+) vector (Novagen) by insertion of a tobacco etch virus (TEV) 
protease cleavage site following a N terminal hexa-histidine and protein A tag. The 
2
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genes were amplified by PCR using T4 primers (New England Biolabs). The resulting 
PCR products and pETM-11 were double digested with NcoI and BamHI enzymes 
(New England Biolabs) before ligation. The construct was verified by sequencing.
The human p531-312, and FOXO486-206 DNA sequences were codon optimized for 
protein production in bacterial cells and flanked by NcoI and BamHI restriction sites. 
The coding region was cloned into a modified pETM-11 bacterial expression vector 
which was derived from a pET-24d(+) vector (Novagen) by insertion of a tobacco 
etch virus (TEV) protease cleavage site following an N terminal hexa-histidine and 
protein A tag.
Unlabeled and uniformly (15N) labelled protein was produced in freshly 
transformed E. coli BL-21 (DE3) cells. A single colony was inoculated in Luria-Bertani 
medium (20 ml) with kanamycin (25 mg l-1) and cultured at 37 °C overnight. From this, 
an aliquot (1 ml) was added to either 1 l unlabeled Luria-Bertani medium or 1 l 15N 
labelled M9 minimal medium (100 mM KH2PO4, 50 mM K2HPO4, 60 mM Na2HPO4, 
14 mM K2SO4, 5 mM MgCl2; pH 7.2 adjusted with HCl and NaOH with 0.1 dilution of 
trace element solution (41 mM CaCl2, 22 mM FeSO4, 6 mM MnCl2, 3 mM CoCl2, 1 
mM ZnSO4, 0.1 mM CuCl2, 0.2 mM (NH4)6Mo7O24, 17 mM EDTA) with kanamycin (25 
mg l-1) in which 15N-NH4Cl (2 g l-1) was the only source of nitrogen for NMR isotope 
labelling purposes, respectively (Cambridge Isotope Laboratories, Inc). The culture 
was incubated at 37 °C and shaken at 200 rpm until the OD600 reached 0.8. Protein 
expression was induced with 1 mM β-D-1-thiogalactopyranoside (IPTG) at 18 °C. 
The cells were pelleted after 20 hours by centrifugation using a Fiberlite F9-6x1000 
rotor in a Sorvall LYNX 6000 Superspeed centrifuge at 2,000 g for 20 minutes, 
re-suspended in 40 ml lysis buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 
20 mM imidazole, 20 % glycerol, 2 mM TCEP, 250 units of Benzonase® Nuclease 
and bacterial Protease Inhibitor Cocktail (Amresco; AEBSF, E-64, Bestatin, EDTA 
and Pepstatin) and were subsequently lysed by sonication. Lysates were cleared 
by centrifugation for 45 min at 4 °C (12 000 r.p.m.; Sorvall Lynx 6 000) and filtration 
(0.45 μm cellulose acetate syringe filters). Proteins were purified using Ni-NTA resins 
for immobilized metal affinity chromatography. Lysate was applied on the column 
and contaminants were removed using Wash buffer 1 (50 mM Tris, pH 7.5, 150 
mM NaCl, 20 mM imidazole and 2 mM TCEP) and Wash buffer 2 (50 mM Tris, pH 
7.5, 1 M NaCl, 20 mM imidazole and 2 mM TCEP). Protein was eluted (50 mM Tris, 
pH 7.5, 1 M NaCl, 500 mM imidazole and 2 mM TCEP) and the His6-Protein A tag 
was cleaved overnight at 4 °C using 2 (w/w) % of 1 mg/ml recombinant His-tagged 
TEV protease. The protein solution was buffer exchanged to Wash buffer 1 using 
HiPrep 26/10 Desalting column on an ÄKTA Pure system (GE Healthcare) at room 
temperature. Cleaved protein was repurified from the cleaved fusion tag and TEV 
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protease by loading on a Ni-NTA resin column and 5 ml of the flow through was 
applied to a size-exclusion column (HiLoad Sepharose 16/600 75 pg, GE Healthcare) 
on an ÄKTA Pure system (GE Healthcare) at RT. The corresponding running buffer 
was composed of 50 mM sodium phosphate, pH 6.5, 150 mM NaCl and 1 mM DTT.
NMR spectroscopy
Samples for NMR measurements contained 300 µM 15N labeled FOXO486-206 
protein in 50 mM sodium phosphate, pH 6.5, 150 mM NaCl and 1 mM DTT with 10% 
2H2O added for the lock signal. For NMR titrations, 0.2, 0.4, 0.8 and 1.0 stochiometric 
equivalents of p531-312 (corresponding to 60, 120, 240 or 300 µM, respectively) and 
1.0 and 2.0 stochiometric equivalents of FOXO4-DRI (corresponding to 300 or 600 
µM, respectively) were added. 1H-15N HSQC NMR spectra were recorded at 298 K on 
a 700 MHz Bruker NMR spectrometer. All spectra were recorded with an interscan 
delay of 1.0 s, spectral widths of 15.9/30 ppm, centered at 4.7/118.0 ppm in 1H/15N, 
with 1,024 and 256 points, respectively, and 16 scans per increment. NMR chemical 
shift assignments of FOXO486-206 were obtained from HNCACB and HNCA spectra 
using 500 µM of uniformly 15N,13C labeled protein in the aforementioned buffer at 
298K on a 900 MHz Bruker Avance III NMR spectrometer equipped with a TCI 
cryoprobe.
Immunofluorescence and Structured Illumination Microscopy
Cells (typically 20,000) were grown on coverslips and after the indicated treatment 
fixed with formalin. Subsequently, cells were washed in Tris Buffered Saline (TBS) 
and permeabilized for 2-5 min in 2% Triton X-100 in TBS, depending on the antibody. 
Especially, the FOXO4 antibody (Cell Signaling) seemed to work better with shorter 
permeabilization times. To reduce background staining, the cells were quenched 
for 10min with 50nM glycine in TBS and blocked for 30min with 5% Normal Horse 
Serum (NHS) or Normal Goat Serum (NGS) in 0,2% gelatin-TBS solution, depending 
on the isotype of the secondary antibody. Subsequently, 30µl droplets containing 
primary antibody dilutions were placed on parafilm in a dark moisture chamber. The 
coverslips were placed facing the droplets and incubated overnight at 4˚C. The next 
day, the coverslips were lifted by adding a small volume (~200µl) of TBS-Gelatine 
under the coverslip and transferred back to the 24-well plate. After washing 3x 20min 
with 1ml 0,2% gelatin-TBS secondary antibody incubation occurred as described 
for the primary antibody and the coverslips were incubated for one hour at room 
temperature. Following 3x 10min washes with 1ml 0,2% TBS-Gelatin and 1 wash 
with regular TBS the slides were mounted using soft set mounting medium with 
DAPI (Vectashield) and sealed with nail polish. Structured Illumination Microscopy 
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was performed using a Zeiss Elyra PS1 microscope using a 63x 1.4 (n.a.) plan 
apo chromate oil immersion lens and 5 phases and 5 rotations of the illumination 
pattern. Intensity plots of individual pixels taken from a straight line in indicated 
immunofluorescence images were generated by twin slicer analysis using Huygens 
Professional 4.0 software (SVI, The Netherlands). Images were cropped and 
processed in Adobe Photoshop. When comparisons were made between images 
of the same experiment, all levels were adjusted equally and the ratio between the 
levels was not altered.
Quantitative real-time PCR
mRNA was extracted using the Cells-to-Ct kit (Ambion). QPCR was performed 
using the Universal Probe Library system (Roche) with the following primer/probe 
combinations (5’-3’), also listed in Table S1:
FOXO1 (NM_002015.3): Fwd: tggttttagaaacccaagttcc, Rev: ttggcaccaagttcagttaca. 
UPL75
FOXO3 (NM_001455.3): Fwd: cagtagggcctgtgatttcc, Rev: cagcagaccaacactgttcac. UPL73
FOXO4 (NM_005938.2): Fwd: acgagtggatggtccgtact, Rev: gtggcggatcgagttcttc. UPL18
P21Cip1 (CDKN1A; NM_000389.3): Fwd: cgaagtcagttccttgtggag, Rev: catgggttctgacggacat. 
UPL82
ETS2 (NM_005239.4): Fwd: cagcgtcacctactgctctg, Rev: agtcgtggtctttgggagtc. UPL27
Tubulin (NM_006009.2): Fwd: cttcgtctccgccatcag, Rev: ttgccaatctggacacca. UPL58
Immunoblotting
The dishes were washed 2x with ice-cold PBS, lysed in 1x Laemli sample buffer, 
and subjected to standard SDS-PAGE using separate 4%-12% Bis-Tris gels, after 
which the proteins were overnight transferred at 4ºC to polyvinylidene fluoride 
membranes. The membranes were blocked using 2% BSA in Tris-buffered saline, 
0.05% TWEEN (TBS-T) for 60min and incubated overnight at 4ºC with the indicated 
primary antibodies. Following at least two 20min washing steps with TBS-T, the 
membranes were incubated with secondary antibodies for 60min. Following at least 
two 15min washing steps the membranes were developed with Enhanced Chemical 
Luminescence (Perkin Elmer). Images were cropped and equally processed in Adobe 
Photoshop.
Cell viability assays
The cells were plated in triplicate in 96-well plates (typically 7000 senescent and 
2000 non-senescent cells). Unless otherwise indicated, cell viability was assessed 
6d after plating, using the AQueousOne Solution Cell Proliferation Assay (Promega). 
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10 ul of CellTiter AQueousOne Solution in 100ul fresh culture medium was added to 
the wells before a 1-3 hour incubation at 37˚C. Absorbance was measured at 490nm 
at a GloMax 96 well plate reader (Promega). A Mock-treated and a Puromycin (10μg/
ml)-treated condition were used to set the maximal and minimal viability values, 
respectively, to which the experimental values were normalized.
Cell density assays
Stably transduced and Puromycin-selected IMR90 cells were plated in 24-well 
plates in triplicate. After 3d, cells were fixed in methanol and stained with 0.5% crystal 
violet in 25% methanol. The plates were dried, and cell density was quantified by 
destaining in 10% acetic acid and measuring absorbance of the solution at 560 nm.
Apoptosis assays
To assess apoptosis, two separate assays were used.
TUNEL staining was performed by permeabilizing cells fixed on coverslips for 2min with 
0.1% Triton X-100 in 0.1% sodium citrate, followed by labeling with 10% TUNEL enzyme 
vs. label solution for 45min (Roche). Objective analysis of the percentage of TUNEL-
positive cells was performed using CellProfiler software v2.3 by scoring the # of TUNEL 
positive objects filtered over DAPI-positive objects (Nuclei). Only TUNEL positive objects 
were considered that were also DAPI positive.
For the Cytochrome-C release assay, cells were seeded on coverslips in a 24-well plate 
and incubated for 5d total with the pan-caspase-inhibitor QVD-OPH (20μM in 500µl). The 
media was refreshed on day 3. Subsequently, the cells were processed for Cytochrome-C 
positivity by immunofluorescence. We measured the percentage of cells that showed a 
mitochondrial release of mitochondrial Cytochrome-C, identified either as diffuse staining, 
or complete absence.
Real-time cell density assay
Real-time cell density was measured using an xCELLigence detection system 
(ACEA Biosciences). Prior to the measurement, 50 µL DMEM 10% FCS was 
added to each well of an E-plate view 16 (Roche) to establish background signal. 
Non-senescent (2000 cells per well) and senescent (5000 cells/well) IMR90 
fibroblasts were then plated in 150 µl medium. 16h later the E-plate was placed 
in the xCELLigence reader and the cell density was recorded every 30min. The 
cells were treated with 25uM FOXO4 peptide 8h after starting the measurements. 
Measurements continued for the indicated intervals.
2
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Real-time imaging of Caspase-3/7 activation
Cells were plated in 4-well Poly-L-Lysine coated glass bottom 35mm dishes 
(D141410; Matsumi, Japan) and incubated with NucView488 Caspase-3 (4440; 
Essen Bioscience). FOXO4-DRI or PBS was added and the cells were transferred 
to a Heat and CO2-controlled incubator, attached to a LSM510 confocal microscope 
(Zeiss). 8h after addition, real-time imaging was initiated and every 30min a grid of 
3x3 pictures was recorded. The imaging continued for another 6 days and the images 
were concatenated using Zen imaging software (Zeiss; See Mov3+4).
Genotyping of mice
For PCR genotyping the following primers were used (See also Table S1):
For p16::3MR-1: p16::3MR1: 5’-AACGCAAACGCATGATCACTG-3’ and p16::3MR-2: 
5’-TCAGGGATGATGCATCTAGC-3’. Positive animals show a band at 202bp.
For XpdTTD/TTD: p145: CCCGGCTAGAGTATCTGC, p184: GCCGGAATACGGGGCCA 
and pβrev :TCTATGGTTAAGTTCATGTCATAGGAAGGGGAGAA.
Design of mouse experiments
For the calculation of the estimated sample size a power analysis was performed 
according to the formula: n= 2(Zα/2+Zβ)
2 * σ2/Δ2, with a power (1-β) of 80% and a 
significance (α) of 0.05. Prior to the study, pilot experiments were performed to 
determine the differences in plasma [Urea] of 26wk old wt vs. XpdTTD/TTD mice. This 
led to a Δ and σ such that a sample size of 7 mice per group were estimated to be 
required to see differences in such experiments. This is shown in Fig. 6K. Later, is 
was found that sample sizes could be reduced when using mice of older age. This 
was applied in Fig. 6L and Fig. 7. For other assays, no information on Δ and σ was 
available and similar, or less stringent, sample sizes were deemed necessary. We only 
mice included mice that were of sufficient body weight at the start of the experiment, 
typically at least 80% of the average littermate weight of the same sex and genotype.
Assessment of running wheel activity
For assessment of running wheel behavior, we only included mice which at 
baseline ran at least 0.1km/day. Running wheel activity was continuously measured 
and plotted in km/day. The mice were placed in running wheel cages with ample time 
to adjust and get trained in using the wheel. After withdrawal of a blood sample, the 
mice were allowed to recover for at least 1 day and the average running wheel activity 
over the next two days was taken as baseline value. The mice were subsequently 
treated with FOXO4-DRI, or PBS (Mock) and at t=21d after baseline (t=18d after 1st 
treatment) the average running wheel activity over 4 days was scored. The ratio of 
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mice of both sexes from four independent experiments was calculated and the % 
activity plotted in Fig. 5I. Note that in some cases blood samples were taken at t=9 
after treatment causing a temporary dip in activity.
Fur density analysis
XpdTTD/TTD mice show reduced fur density (de Boer et al., 2002; de Boer et al., 
1998). To score any changes that might occur over time, the phenotype was ranged 
from 0-4 where 0 was very patched and 4 was wildtype. Each mouse was scored 
before and after the experiment as indicated in Fig. 5C and Fig. S5A. The final 
score was determined as the ratio (final-baseline)/baseline and the % change was 
subsequently plotted. Following several initial pilot observations, the experiment 
shown in Fig. 5C contains mice from two independent cohorts. For naturally aged 
mice (Fig. 7D), only males were included, since we did not observe significant hair 
loss in females. In these cohorts, 80% showed (varying degrees of) loss of hair at 
the beginning (115+wks), or developed it over the course of the experiment.
Infrared-measurements of abdominal temperature
From handling wt vs. XpdTTD/TTD mice, there appeared to be a difference in surface 
temperature. This we reasoned to be caused by changes in fur density. To further 
quantify such changes, the abdominal temperature was subsequently measured 
using an infrared thermometer. Even though the variation in individual measurements 
per animal was relatively large, XpdTTD/TTD mice showed a significantly higher average 
infrared-measured abdominal temperature in general (See also Fig. 5E). There were 
also mice with a relatively normal temperature. To assess the effect of FOXO4-DRI 
vs. PBS therefore only mice with a baseline temperature >34 degrees were included 
as the window of visualizing any changes would otherwise be too small.
Immunohistochemistry
For immunohistochemistry, paraffin sections of liver and intestine specimens were 
deparaffinized, rehydrated in decreasing concentrations of ethanol, treated for 10 
minutes with 3% H2O2 to quench endogenous peroxidase activity and heated to 100°C 
for 1 h in 10 mM sodium citrate buffer, pH 6, for antigen retrieval. Subsequently the 
tissues were processed as for immunofluorescence. Paraffin embedded heart tissue was 
serially sectioned into 5 µm slices, deparaffinized and rehydrated before Hematoxylin-
Eosin (HE) staining or Picro Sirius Red staining was performed. For the HE staining, 
the sections were stained in Gills Hematoxylin (Sigma) for 4 minutes and 30 seconds in 
Eosin-Y solution. To stain for collagen, sections were incubated for 60 minutes in Picro 
Sirius Red solution (1g/L in picric acid) and briefly rinsed twice in 0.05% acetic acid.
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For in vivo luminescence, mice were injected i.p. with 15 mg of Xenolight RediJect 
Coelentarazine (Caliper). 20 min later, the mice were anesthetized (2–4 % isoflurane) 
and placed in a dorsal position during imaging. Bioluminescence was measured 
with a Xenogen IVIS-200 Optical in vivo imaging System (Caliper Life Sciences; 5 
min exposure). Photon flux was quantified within a circular region of interest (ROI) 
encompassing the site of substrate injection and the total radiance was corrected 
for time and surface area measured.
Plasma values as measure for tissue function
On the indicated time points, whole blood samples were collected in a Microvette 
with Lithium Heparin (Sarstedt) for plasma separation and spun for 10min at 4.6 x g. The 
(clear) supernatant was transferred into regular 1.5ml tubes and spun again for 5min at 
4.6 x g. The supernatants were transferred again into 1.5ml tubes, snap frozen in liquid 
N2 and stored at -80°C. [AST] was measured using an AST Activity Assay Kit (Sigma). 
The samples were incubated with 100µl reaction mix in a 96 well plate and placed at 
37˚C. The absorbance at 450nm was determined after 2 minutes for baseline analysis 
and after 40 minutes for a final analysis. [Urea] was measured using a QuantiChrom 
Urea Assay Kit (Gentaur). The samples were incubated in 200µl reaction mix for 10 
minutes at room temperature before absorbance was measured at 520nm. [Creatinine] 
was measured using Creatinine Assay Kit (Sigma). Samples were incubated with 50µl 
reaction mix at 37˚C for 60 minutes and the absorbance was measured at 570nm. 
Ratios comparing plasma values after treatment compared to baseline were determined 
and plotted as % over baseline in scatter plots.
Post mortem SA-β-GAL assay
All tissues were flash frozen in Optimal Cutting Temperature (OCT) Tissue Tek 
and stored until ready for processing. Subsequently, 10μm slices were cryosectioned 
and placed on charged microscopy slides. These were washed with ice-cold PBS for 
5min and fixed in formalin for 15min on ice. Immediately after fixation the samples 
were washed once briefly with MilliQ and stained overnight at 37ºC with fresh SA-β-
GAL solution (pH 6.0), containing 2,5 mM Na2HPO4, 7,4 mM Citric Acid, 0.15M NaCl, 
2mM MgCl2, 5 mM Potassium Ferricyanide, 5 mM Potassium Ferrocyanide and 25ul/
ml 4% X-gal in DMF. Samples were mounted using soft set mounting medium with 
DAPI (Vectashield) and sealed with nail polish. Cultured cells were treated similarly.
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QUANTIFICATION AND STATISTICAL ANALYSIS
Unpaired Student’s t-tests were used to calculate the p value for pairwise 
comparisons. For multiple comparisons p-values were calculated using one-way 
ANOVA with Bonferroni post-test correction (Graph-Pad Prism). For comparisons 
of fold change differences an unpaired one-tailed t-test on the 2Log fold differences 
was applied. For the comparison of RLUC expression in naturally aged p16::3MR 
mice (Fig. 7A) and the change in abdominal temperature (Fig. 5E, right panel) a 
N-1 binary comparison test was performed. When averaging quantifications of 
single analyses, the “sum of squares”-rule was applied. The following indications of 
significance were used throughout the manuscript: * p<0.05, ** p<0.01.
DATA AND SOFTWARE AVAILABILITY
The RNA-Seq data obtained in this study has been uploaded to NCBI GEO 
datasets, under accession number GSE94395 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE94395).
The software to analyze the data is available at http://rna-ome.erasmusmc.nl/.
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Figure S1. Related to Figure 1. A) Table showing color-coded changes in mRNA expression, fold 
change (F.C.) and p-values of the indicated apoptosis-associated genes in senescent vs. control 
IMR90. This figure is complementary to Fig. 1A showing the cell-intrinsic apoptosis pathway. B) 
Table showing the fold change and p-values of apoptosis-associated transcriptional regulators 
with FOXO4 highlighted in green. This figure complements Fig. 1B, which show a volcano plot of 
all transcriptional regulators. C) Treatment plan and visualization of cell density of senescent cells 
transduced with shRNAs against FOXO4. This figure is complementary to Fig. 1H).
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Supplementary figure 2
Figure S2. Related to Figure 2. A) Quantification of the % of cells containing 3 or more FOXO4 
foci after non-senescence inducing levels of gamma irradiation (0.5Gy and 2Gy) or senescence-
inducing levels (10Gy) in time. B) Immunofluorescence of FOXO4 foci in and SA-β-GAL positive 
senescent cell. C) Immunofluorescence showing formation of foci, after 200nM Rotenone, 8J/
m2 UVC and Oncogene-induced senescence by stable ectopic expression of HRASG12V. D) 
Quantification of mouse NIH3T3 cells expressing 3 or more FOXO4 foci 7d after 10Gy IR, showing 
cross-species conservation of Foci formation. E+F) Visualization and quantification of the size of 
53BP1, PML and FOXO4 foci in time after senescence induction, showing that 53BP1 foci and 
PML bodies expand, but FOXO4 foci remain the same in size. G-I) High magnification and pixel 
quantification of costainings between FOXO4 and PML (G), 53BP1 (H) and phosphorylated ATM-
substrates (I) in nuclei of senescent IMR90. J+K) Heat-maps from two independent databases 
and independently scored (z-scored vs. non-z-scored), comparing FOXO1, 3 and 4 expression 
difference in various tissues. J) Z-scored mRNA expression profiles from Proteomicsdb(Wilhelm 
et al., 2014). K) Non-z-scored mRNA expression profiles from Proteinatlas(Uhlen et al., 2015). L) 
Sequence comparison of the sequence used for FOXO4-DRI revealing it to be identical in human 
and mouse FOXO4, but differs in 9 and 8 amino acids from FOXO1 and FOXO3a, respectively.
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Figure S3. Related to Figure 3. A) Viability assay on control IMR90, BJ and WI-38 and counterparts 
induced to senesce by 10Gy IR, and incubated with FOXO4-DRI or PBS. B) Viability assays 
comparing the effects of the cocktail of Quercetin (20μM) with increasing doses of Dasatinib, ABT-
737 or FOXO4-DRI when applied once on control or senescent IMR90. C) Treatment schedule for 
Fig. 3E. D) Immunoblot determining the effect of two independent short hairpins against p53 on 
p53 expression. NIH3T3 cells were transiently transfected with the indicated shRNAs used in Fig. 
3F in combination with pBABE-Puro. After 2d Puromycin selection the samples were processed 
for immunoblotting.
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Supplementary figure 4
Figure S4. Related to Figure 4. A) Schematic overview of the p16::3MR construct, which comprises 
the promoter of p16ink4a that drives expression of a Trimodality reporter (3MR) consisting of 
Renilla Luciferase (RLUC) for bioluminescence detection, RFP for fluorescence detection and 
TK-HSV which can be used to induce selective clearance using Ganciclovir (GCV). B) Reduced, 
but subsequent doses of FOXO4-DRI, show to be more efficient in targeting Doxorubicin-senescent 
IMR90, than 1x high dose treatment. Senescent or Doxo-senescent IMR90 cells were exposed 1x 
to the final concentration of FOXO4-DRI, or 3x 1/3 that dose. The SI75 was compared between 
both treatment regimes. C) Immunofluorescence for IL6 in control or Doxo-senescent cells. D) 
Representative mice and quantification of p16-driven RLUC radiance in 5 mice i.p. injected with 
10mg/kg Doxorubicin and analyzed on the indicated time-points. E) Visualization of change in 
Doxorubicin-induced p16-mediated senescence through bioluminescence in mice treated as in 
Fig. 4I, but with 5x 25mg/kg i.p GCV (day 1,2,3,4,5) for semigenetic clearance of senescence, or 
the same regimen in addition to 3x i.v. 5mg/kg FOXO4-DRI (day 1,3,5). F) Quantification of the % 
AST in plasma of mice from Fig. S4E after treatment vs. baseline.
2




Figure S5. Related to Figure 5. A) Overview of the fur status of the indicated XpdTTD/TTD mice 
before or after treatment with PBS (Left columns) or FOXO4-DRI (Right columns), respectively. 
The mice were scored 0-4 where 4 is fur as seen in wildtype mice and 0 is most reduced. The % 
change was calculated for each mouse and plotted in Fig. 5D. Red arrows indicate deterioration 
of the indicated area over time, whereas green arrows indicate improvement. B) Example of 
difference in behavior of XpdTTD/TTD mice treated with PBS, or FOXO4-DRI. To address this 
more quantitatively, the responsiveness to gentle stimuli was measured as described in Fig. 5F.
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Supplementary figure 6
Figure S6. Related to Figure 6. A) Schematic overview of kidney slice culture experiment and 
subsequent analysis. Fresh kidneys were isolated and sectioned in 200μM slices. These were 
placed in 24-well plate wells in tissue culture medium while rotating at 60rpm (See also(Kruiswijk 
et al., 2016)). Following treatment with shRNAs the slices were processed for TUNEL staining and 
the percentage positive cells is objectively scored. B) Treatment plan for kidney slice experiments in 
Fig. 6E and Fig. S6C-D. C) Example of shGFP and shFOXO4 (mouse) transduced 130w WT kidney 
slices stained for TUNEL (left), segmented for DAPI (middle) and scored for percentage TUNEL 
positive (right) using Cellprofiler V2.3. D) Quantification of n=6 kidney slices processed as in C). 
E) Whole blood analysis of the mice in Fig. 6F. F) Heart sections of PBS, or FOXO4-DRI treated 
wt mice (26w), stained by H&E for general pathology, and Picro Sirius Red to visualize collagen 
deposition. N>4. No apparent abnormalities were observed. G) FOXO4-DRI does not significantly 
alter total body weight, nor kidney weight (normalized to total body weight) of WT or XpdTTD/TTD 
mice. This figure complements Fig. 6G, J, K and L, by showing that while FOXO4-DRI does not 
influence total kidney mass it does improve renal function.
2




Figure S7. Related to Figure 7. A) Quantitative representation of the % p16-driven senescence 
(RLUC) in naturally aged mice treated with FOXO4-DRI or PBS. Note the large biological spread in 
signal. B) Overview of the fur status of the indicated naturally aged mice before or after treatment 
with PBS (Left columns) or FOXO4-DRI (Right columns), respectively. Right panel: quantification 
of the % change as also described in Fig. 5D. C) Quantification of the % change in body weight of 
naturally aged mice treated as in Fig. 7B-I (Left panel), or Fig. 7J (Right panel).
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Mov. 1. Related to Fig. 2D. Structured Illumination Microscopic (SIM) image of 
the nucleus of a senescent IMR90 cell.
Senescent IMR90 cells were stained for FOXO4 (Alexa488; Green), 53BP1 (Alexa594; 
Red) and PML (Alexa647; Purple) and DAPI (Blue). A SIM image was taken and this 
movie shows the combinations of the respective colors of a representative image. See 
also Mov. 2.
Mov. 2. Related to Fig. 2D. 3D reconstruction of a representative FOXO4/53BP1/
PML cluster in the nucleus of a senescent IMR90 cell.
Senescent IMR90 cells were stained for FOXO4 (Alexa488; Green), 53BP1 (Alexa594; 
Red) and PML (Alexa647; Purple) and DAPI (Blue). A SIM image was taken and the focal 
structure indicated by the yellow line in Fig. 2D was processed for 3D reconstruction, 
using Amira software. See also Mov. 1.
Mov. 3. Related to Fig. 3H. Lack of Caspase-3 activity in control IMR90 cells 
incubated with FOXO4-DRI.
Control IMR90 cells were incubated with a dye that turns green upon activation of 
Caspase-3 (NucView488 Caspase-3) and 25µM FOXO4-DRI. After 8h the cells were 
processed for real-time imaging for 6 days in total. See also Mov. 4
Mov. 4. Related to Fig. 3H. Induction of Caspase-3 activity in senescent IMR90 
cells incubated with FOXO4-DRI.
IR-senescent IMR90 cells were incubated with a dye that turns green upon activation 
of Caspase-3 (NucView488 Caspase-3) and 25µM FOXO4-DRI. After 8h the cells were 
processed for real-time imaging for 6 days in total. See also Mov. 3.
2




Baker, D.J., Childs, B.G., Durik, M., Wijers, M.E., Sieben, C.J., Zhong, J., Saltness, R.A., 
Jeganathan, K.B., Verzosa, G.C., Pezeshki, A., et al. (2016). Naturally occurring 
p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184-189.
Beydoun, T., Deloche, C., Perino, J., Kirwan, B.A., Combette, J.M., and Behar-Cohen, F. 
(2015). Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with 
intraocular inflammation: a safety and tolerability study. J Ocul Pharmacol Ther 31, 
93-99.
Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, 
J., and Bonny, C. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects 
against excitotoxicity and cerebral ischemia. Nat Med 9, 1180-1186.
Botter, S.M., Zar, M., van Osch, G.J., van Steeg, H., Dolle, M.E., Hoeijmakers, J.H., Weinans, 
H., and van Leeuwen, J.P. (2011). Analysis of osteoarthritis in a mouse model of the 
progeroid human DNA repair syndrome trichothiodystrophy. Age (Dordr) 33, 247-260.
Brown, J.P., Wei, W., and Sedivy, J.M. (1997). Bypass of senescence after disruption of 
p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277, 831-834.
Cahu, J., Bustany, S., and Sola, B. (2012). Senescence-associated secretory phenotype 
favors the emergence of cancer stem-like cells. Cell Death Dis 3, e446.
Campisi, J. (2013). Aging, cellular senescence, and cancer. Annu Rev Physiol 75, 685-705.
Chang, J., Wang, Y., Shao, L., Laberge, R.M., Demaria, M., Campisi, J., Janakiraman, K., 
Sharpless, N.E., Ding, S., Feng, W., et al. (2016). Clearance of senescent cells by 
ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature medicine 22, 
78-83.
Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez, 
P.Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal 
cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. 
PLoS Biol 6, 2853-2868.
Damodar, G., Smitha, T., Gopinath, S., Vijayakumar, S., and Rao, Y. (2014). An evaluation 
of hepatotoxicity in breast cancer patients receiving injection Doxorubicin. Ann Med 
Health Sci Res 4, 74-79.
de Boer, J., Andressoo, J.O., de Wit, J., Huijmans, J., Beems, R.B., van Steeg, H., Weeda, 
G., van der Horst, G.T., van Leeuwen, W., Themmen, A.P., et al. (2002). Premature 
aging in mice deficient in DNA repair and transcription. Science 296, 1276-1279.
de Boer, J., de Wit, J., van Steeg, H., Berg, R.J., Morreau, H., Visser, P., Lehmann, A.R., 
Duran, M., Hoeijmakers, J.H., and Weeda, G. (1998). A mouse model for the basal 
transcription/DNA repair syndrome trichothiodystrophy. Mol Cell 1, 981-990.
Voorbereid document - Marjolein Baar.indd   72 17-04-19   17:20
73
Targeted apoptosis of senescent cells
de Keizer, P.L. (2017). The Fountain of Youth by Targeting Senescent Cells? Trends Mol 
Med 23, 6-17.
de Keizer, P.L., Burgering, B.M., and Dansen, T.B. (2011). Forkhead box o as a sensor, 
mediator, and regulator of redox signaling. Antioxidants & redox signaling 14, 1093-
1106.
de Keizer, P.L., Packer, L.M., Szypowska, A.A., Riedl-Polderman, P.E., van den Broek, N.J., 
de Bruin, A., Dansen, T.B., Marais, R., Brenkman, A.B., and Burgering, B.M. (2010). 
Activation of forkhead box O transcription factors by oncogenic BRAF promotes 
p21cip1-dependent senescence. Cancer research 70, 8526-8536.
Degenhardt, K., Sundararajan, R., Lindsten, T., Thompson, C., and White, E. (2002). Bax 
and Bak independently promote cytochrome C release from mitochondria. The 
Journal of biological chemistry 277, 14127-14134.
Deloche, C., Lopez-Lazaro, L., Mouz, S., Perino, J., Abadie, C., and Combette, J.M. (2014). 
XG-102 administered to healthy male volunteers as a single intravenous infusion: a 
randomized, double-blind, placebo-controlled, dose-escalating study. Pharmacol 
Res Perspect 2, e00020.
Demaria, M., Ohtani, N., Youssef, S.A., Rodier, F., Toussaint, W., Mitchell, J.R., Laberge, 
R.M., Vijg, J., Van Steeg, H., Dolle, M.E., et al. (2014). An essential role for senescent 
cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 31, 722-733.
Di, L.A., Linke, S.P., Clarkin, K., and Wahl, G.M. (1994). DNA damage triggers a prolonged 
p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. 
Genes Dev 8, 2540-2551.
Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, 
M., Rubelj, I., and Pereira-Smith, O. (1995). A biomarker that identifies senescent 
human cells in culture and in aging skin in vivo. ProcNatlAcadSciUSA 92, 9363-9367.
Eijkelenboom, A., and Burgering, B.M. (2013). FOXOs: signalling integrators for homeostasis 
maintenance. Nat Rev Mol Cell Biol 14, 83-97.
Ewald, J.A., Desotelle, J.A., Wilding, G., and Jarrard, D.F. (2010). Therapy-induced 
senescence in cancer. J Natl Cancer Inst 102, 1536-1546.
Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D.D., Guralnik, J.M., 
and Longo, D.L. (2005). The origins of age-related proinflammatory state. Blood 
105, 2294-2299.
Freund, A., Laberge, R.M., Demaria, M., and Campisi, J. (2012). Lamin B1 loss is a 
senescence-associated biomarker. Mol Biol Cell 23, 2066-2075.
Freund, A., Patil, C.K., and Campisi, J. (2011). p38MAPK is a novel DNA damage response-
independent regulator of the senescence-associated secretory phenotype. EMBO 
J 30, 1536-1548.
2
Voorbereid document - Marjolein Baar.indd   73 17-04-19   17:20
74
Chapter 2
Gowda, S., Desai, P.B., Kulkarni, S.S., Hull, V.V., Math, A.A., and Vernekar, S.N. (2010). 
Markers of renal function tests. N Am J Med Sci 2, 170-173.
Guichard, G., Benkirane, N., Zeder-Lutz, G., van Regenmortel, M.H., Briand, J.P., 
and Muller, S. (1994). Antigenic mimicry of natural L-peptides with retro-inverso-
peptidomimetics. Proceedings of the National Academy of Sciences of the United 
States of America 91, 9765-9769.
Henderson, T.O., Ness, K.K., and Cohen, H.J. (2014). Accelerated aging among cancer 
survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book, e423-430.
Herce, H.D., and Garcia, A.E. (2007). Molecular dynamics simulations suggest a 
mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. 
Proceedings of the National Academy of Sciences of the United States of America 
104, 20805-20810.
Hoeijmakers, J.H. (2009). DNA damage, aging, and cancer. N Engl J Med 361, 1475-1485.
Hosaka, T., Biggs, W.H., 3rd, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., and Arden, 
K.C. (2004). Disruption of forkhead transcription factor (FOXO) family members in 
mice reveals their functional diversification. Proc Natl Acad Sci U S A 101, 2975-2980.
Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., and 
Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 
114, 1299-1307.
Kruiswijk, F., Hasenfuss, S.C., Sivapatham, R., Baar, M.P., Putavet, D., Naipal, K.A., van 
den Broek, N.J., Kruit, W., van der Spek, P.J., van Gent, D.C., et al. (2016). Targeted 
inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. 
Oncogene 35, 2166-2177.
Kruiswijk, F., Labuschagne, C.F., and Vousden, K.H. (2015). p53 in survival, death and 
metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16, 393-405.
Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The 
hallmarks of aging. Cell 153, 1194-1217.
Lyman, J.L. (1986). Blood urea nitrogen and creatinine. Emerg Med Clin North Am 4, 223-233.
Martins, R., Lithgow, G.J., and Link, W. (2016). Long live FOXO: unraveling the role of 
FOXO proteins in aging and longevity. Aging Cell 15, 196-207.
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U.M. 
(2003). p53 has a direct apoptogenic role at the mitochondria. Molecular cell 11, 577-
590.
Munoz-Espin, D., Canamero, M., Maraver, A., Gomez-Lopez, G., Contreras, J., Murillo-Cuesta, S., 
Rodriguez-Baeza, A., Varela-Nieto, I., Ruberte, J., Collado, M., et al. (2013). Programmed 
cell senescence during mammalian embryonic development. Cell 155, 1104-1118.
Voorbereid document - Marjolein Baar.indd   74 17-04-19   17:20
75
Targeted apoptosis of senescent cells
Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W.H., 3rd, Arden, K.C., and Accili, D. (2003). 
The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 
4, 119-129.
Orjalo, A.V., Bhaumik, D., Gengler, B.K., Scott, G.K., and Campisi, J. (2009). Cell surface-
bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 
cytokine network. Proceedings of the National Academy of Sciences of the United 
States of America 106, 17031-17036.
Paik, J.H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, 
J.W., Carrasco, D.R., et al. (2007). FoxOs are lineage-restricted redundant tumor 
suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323.
Renault, V.M., Rafalski, V.A., Morgan, A.A., Salih, D.A., Brett, J.O., Webb, A.E., Villeda, 
S.A., Thekkat, P.U., Guillerey, C., Denko, N.C., et al. (2009). FoxO3 regulates neural 
stem cell homeostasis. Cell Stem Cell 5, 527-539.
Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, 
A., Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage 
signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell 
Biol 11, 973-979.
Rodier, F., Munoz, D.P., Teachenor, R., Chu, V., Le, O., Bhaumik, D., Coppe, J.P., Campeau, 
E., Beausejour, C.M., Kim, S.H., et al. (2011). DNA-SCARS: distinct nuclear structures 
that sustain damage-induced senescence growth arrest and inflammatory cytokine 
secretion. J Cell Sci 124, 68-81.
Roninson, I.B. (2003). Tumor cell senescence in cancer treatment. Cancer research 63, 
2705-2715.
Schoenwaelder, S.M., Jarman, K.E., Gardiner, E.E., Hua, M., Qiao, J., White, M.J., 
Josefsson, E.C., Alwis, I., Ono, A., Willcox, A., et al. (2011). Bcl-xL-inhibitory BH3 
mimetics can induce a transient thrombocytopathy that undermines the hemostatic 
function of platelets. Blood 118, 1663-1674.
Suckfuell, M., Lisowska, G., Domka, W., Kabacinska, A., Morawski, K., Bodlaj, R., Klimak, 
P., Kostrica, R., and Meyer, T. (2014). Efficacy and safety of AM-111 in the treatment 
of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled 
phase II study. Otol Neurotol 35, 1317-1326.
Tait, S.W., and Green, D.R. (2010). Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat Rev Mol Cell Biol 11, 621-632.
Vaupel, J.W. (2010). Biodemography of human ageing. Nature 464, 536-542.
Wang, E. (1995). Senescent human fibroblasts resist programmed cell death, and failure 
to suppress bcl2 is involved. Cancer research 55, 2284-2292.
2
Voorbereid document - Marjolein Baar.indd   75 17-04-19   17:20
76
Chapter 2
Wang, F., Marshall, C.B., Yamamoto, K., Li, G.Y., Plevin, M.J., You, H., Mak, T.W., and Ikura, 
M. (2008). Biochemical and structural characterization of an intramolecular interaction 
in FOXO3a and its binding with p53. J Mol Biol 384, 590-603.
Warso, M.A., Richards, J.M., Mehta, D., Christov, K., Schaeffer, C., Rae Bressler, L., 
Yamada, T., Majumdar, D., Kennedy, S.A., Beattie, C.W., et al. (2013). A first-in-
class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of 
p53 ubiquitination in patients with advanced solid tumours. British journal of cancer 
108, 1061-1070.
Wijnhoven, S.W., Beems, R.B., Roodbergen, M., van den Berg, J., Lohman, P.H., Diderich, 
K., van der Horst, G.T., Vijg, J., Hoeijmakers, J.H., and van Steeg, H. (2005). 
Accelerated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by 
features suggestive of caloric restriction. DNA repair 4, 1314-1324.
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E.R., Pirtskhalava, T., White, 
T.A., Johnson, K.O., Stout, M.B., Mezera, V., et al. (2015). JAK inhibition alleviates 
the cellular senescence-associated secretory phenotype and frailty in old age. 
Proceedings of the National Academy of Sciences of the United States of America 
112, E6301-6310.
Yosef, R., Pilpel, N., Tokarsky-Amiel, R., Biran, A., Ovadya, Y., Cohen, S., Vadai, E., Dassa, 
L., Shahar, E., Condiotti, R., et al. (2016). Directed elimination of senescent cells by 
inhibition of BCL-W and BCL-XL. Nat Commun 7, 11190.
Zhou, W., Cao, Q., Peng, Y., Zhang, Q.J., Castrillon, D.H., DePinho, R.A., and Liu, Z.P. 
(2009). FoxO4 inhibits NF-kappaB and protects mice against colonic injury and 
inflammation. Gastroenterology 137, 1403-1414.
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A.C., Ding, H., Giorgadze, N., Palmer, A.K., 
Ikeno, Y., Hubbard, G.B., Lenburg, M., et al. (2015). The Achilles’ heel of senescent 
cells: from transcriptome to senolytic drugs. Aging Cell 14, 644-658.
Voorbereid document - Marjolein Baar.indd   76 17-04-19   17:20
77
Targeted apoptosis of senescent cells
2
Voorbereid document - Marjolein Baar.indd   77 17-04-19   17:20
Voorbereid document - Marjolein Baar.indd   78 17-04-19   17:20
CHAPTER 3
Musculoskeletal senescence: 
A moving target ready 
to be eliminated
Marjolein P. Baar1,2, Eusebio Perdiguero3, Pura Muñoz-Cánoves3,4 and Peter L.J. 
de Keizer1
1 Department of Molecular Cancer Research, Center for Molecular Medicine, Division of Biomedical 
Genetics, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, 3584CG 
Utrecht, the Netherlands
2 Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the 
Netherlands
3 Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), CIBERNED, 
Barcelona, Spain.
4 ICREA and Spanish National Center on Cardiovascular Research (CNIC), Madrid, Spain.
Published in Curr Opin Pharmacol. 2018 Jun;40:147-155. doi: 10.1016/j.coph.2018.05.007.
Voorbereid document - Marjolein Baar.indd   79 17-04-19   17:20
80
Chapter 3
Aging is the prime risk factor for the broad-based development of diseases. Frailty 
is a phenotypical hallmark of aging and is often used to assess whether the 
predicted benefits of a therapy outweigh the risks for older patients. Senescent 
cells form as a consequence of unresolved molecular damage and persistently 
secrete molecules that can impair tissue function. Recent evidence shows 
senescent cells can chronically interfere with stem cell function and drive aging of 
the musculoskeletal system. In addition, targeted apoptosis of senescent cells can 
restore tissue homeostasis in aged animals. Thus, targeting cellular senescence 
provides new therapeutic opportunities for intervention in frailty-associated 
pathologies and could have pleiotropic health benefits.
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Loss of cell-intrinsic and -extrinsic integrity perturbs musculoskeletal 
rejuvenation during aging
Aged individuals can deteriorate exceptionally fast after the onset of complications 
affecting the musculoskeletal system. Tissue erosion due to life-long mechanical 
and biological stress can ultimately result in pathologies such as osteoporosis, 
sarcopenia, and osteoarthritis, and contribute to frailty [1]. While not all elderly 
people develop the same age-related diseases, virtually everyone will experience 
musculoskeletal complications sooner or later. To extend, and possibly even restore, 
healthy life expectancy in old age, it is essential to understand the cellular changes 
underlying musculoskeletal decline. Tissue regeneration by stem-cell differentiation 
is critical in overcoming the relentless day-by-day damage to the musculoskeletal 
system. In young tissues, differentiation proceeds without much hindrance unless 
one exercises excessively or suffers undue levels of stress. However, during aging, 
the number and function of adult stem cells declines [2, 3]. For example, Pax7-
expressing satellite stem cells can replace damaged muscle fibers [4]. Removing 
Pax7-positive cells from mice impairs muscle regeneration after injury [5], whereas 
increased availability of these cells enhances muscle repair [6].
In addition to cell-intrinsic regulation, muscle stem cell regenerative capacity also 
depends intimately on the microenvironment. During aging, the levels of inflammation 
chronically increase, an affect known as inflammaging [7]. Evidence for this is 
provided by studies showing that muscle stem cells (satellite cells) from aged mice 
become more fibrogenic, a conversion mediated by factors from the aged systemic 
environment [8]. In contrast, frailty is reduced by the JAK/STAT inhibitor Ruxolitinib, 
which reduces inflammation in naturally aged mice [9]. Stem-cell impairing cues 
do not necessarily have to come from local sources but can travel over a distance. 
Heterochronic parabiosis experiments showed that transfusion of old blood impairs 
stem cell function in young recipient mice [10], while the transfer of young blood 
factors restoring muscle regeneration and muscle stem-cell activation in aged 
animals [11]. Therefore, there is a great interest in developing methods to interfere 
with the age-associated pro-inflammatory signaling profile. The question is how? 
To address this question, cellular senescence has recently gained attention as a 
potential candidate for intervention.
Signaling noise by senescent cells impedes tissue homeostasis during aging
As we age, each cell in our body accumulates damage. Earlier in life, this 
damage is usually faithfully repaired [12], but over time more and more damage 
gets left behind. This can trigger a molecular chain of events, resulting in chromatin 
remodeling and the entry of cells into a permanent state of growth-factor insensitive 
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cell-cycle arrest, called cellular senescence. Senescence can be invoked in healthy 
cells that experience a chronic damage response, either involving direct DNA 
damage or events that mimic the molecular response, such as telomere shortening or 
oncogenic mutations [13]. As a consequence, these cells undergo an irreversible cell 
cycle arrest, effectively limiting the damage. So far, so good, except that senescent 
cells secrete a broad range of growth factors, pro-inflammatory proteins, and matrix 
proteinases that alter the microenvironment: The Senescence-Associated Secretory 
Phenotype (SASP) [14].
Senescent cells persist for prolonged periods of time and eventually accumulate 
during aging [15]. This also means there is a gradual and, importantly, ever-
present build-up of deleterious molecules. Thus, senescence can have continuous 
detrimental effects on tissue homeostasis during aging. That senescent cells are 
a direct cause of aging was proven beyond a doubt in studies in which senescent 
cells were genetically or pharmacologically removed. In these studies, both rapidly 
and naturally aged mice maintained healthspan for much longer, or even showed 
signs of aging reversal [16-19]. Factors secreted by senescent cells can induce 
pluripotency in vivo[20]. As such, these can impair normal stem cell function by 
forcing a constant state of reprogramming, something we dubbed a “senescence – 
stem lock”[13]. This is supported by observations that factors secreted by senescent 
cells induce pluripotency in vivo [20]. Age-associated inflammation may thus 
deregulate normal stem cell function at different levels, for instance by preventing 
stem cells from producing differentiated daughter cells. Due to the constant secretion 
of SASP factors, senescent cells could thus impair local and distant stem cell 
function and differentiation in times of need. Here, we will highlight the interplay 
between senescence, the SASP and stemness in the individual musculoskeletal 
compartments: Muscle, Bone and Cartilage.
Skeletal muscle: an intrinsic interplay between senescence and stemness
Several reports link senescence to muscle aging and muscle stem cell dysfunction. 
For example, expression of the major senescence marker p16INK4A prevents tissue 
regeneration by satellite cells after damage [21]. Fast-aging BubR1H/H mice develop 
sarcopenia, and after genetic removal of senescent cells, they showed a reduction 
in kyphosis and an increase in muscle fiber diameter, findings suggestive of reduced 
sarcopenia [16]. Likewise, senescence of muscle stem cells occurs in muscles of 
mice with distinct dystrophinopathies, such as Duchenne muscular dystrophy or 
Steinert’s diseases [22-25].
The skeletal muscle stem cell niche is a candidate through which senescent cells 
may exert their deleterious effects. Interleukin 6 (IL-6) is a pleiotropic cytokine that 
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can be released by inflammatory cells and by muscle fibers (acting as a myokine). 
IL6 is also a major component of the SASP[14], and has been shown to regulate the 
transition of satellite cells from a quiescent to an activated state [26]. This is beneficial 
upon acute tissue stress, where IL-6 is transiently released by growing myofibers to 
activate satellite cells and thereby stimulate myogenesis [26]. However, the chronic 
IL-6 signaling caused by senescence during aging would have very detrimental 
effects on muscle function. Indeed, muscle atrophy is linked to high IL-6 levels in 
patients with inflammatory diseases such as cancer [27]. In addition, persistent IL-6 
expression was shown to increase muscle degradation in combination with other 
circulating factors in mice [28, 29]. Interestingly, when IL-6 receptors were blocked 
in mice with ectopic IL-6 expression, atrophy could be attenuated, indicating a direct 
regulation of muscle wasting by IL-6 [30]. Chronic IL-6 signaling causes protein 
degradation in muscle, explaining age-related muscle wasting [31]. Additionally, IL-6 
dependent muscle degradation may be linked to stem cell function. For example, 
senescence induction after muscle injury can promote Pax7 positive unipotent cells 
to undergo reprogramming and regain pluripotency [32]. This process is dependent 
on IL-6 secreted by the senescent cells. Further underscoring the role between the 
senescent niche and stemness in the muscle is provided by elegant work employing 
a system in which the four Yamanaka stem cell factors, Oct4, Sox2, Klf4 and c-Myc 
(OSKM) were transiently expressed in vivo. This resulted in a marked reduction 
in senescence, SASP factors such as IL6 and improved recovery in muscle injury 
experiments[33]. Together, this supports a model we postulated previously that 
because senescence increases locally during aging hotspots are formed of high IL6 
concentrations. This can cause neighboring cells to become pluripotent. However, 
due to the chronic nature of the SASP, senescent cells provide a continuous source 
of IL6 causing these cells remain permanently locked in a pluripotent state and 
rendering them unable to rejuvenate the tissue after injury[13].
Although satellite dysfunction has been linked to sarcopenia, this relationship 
is controversial. Recent studies suggest that the decline in satellite cell function 
during aging is not the cause of sarcopenia [34, 35]. When satellite cells were 
genetically removed over a prolonged period, no difference in muscle mass was 
observed compared with mice that maintained their satellite cells. However, there 
was a clear increase in fibrosis, indicating that satellite cells are indeed crucial for 
muscle homeostasis. Furthermore, several studies show that sarcopenic muscle has 
a reduced ability to recover after injury, which is dependent on satellite cell function 
[5, 21, 35, 36]. Overall, while the role of satellite cells in sarcopenia is still debated, 
there is consensus that Pax7 positive cells are required for regeneration after muscle 
injury and that reduced function of these stem cells leads to age-related frailty.
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Aged muscle fibers show atrophy that is linked to an age-related increase in cellular senescence. 
Satellite cells lose proliferation capacity through senescence induction or the chronic presence of 
SASP factors such as Il-6. Thus, regeneration of damaged tissue is prevented. Additionally, IL-15 
secreted by muscle tissue facilitates NK cell survival in young organisms, while IL-6 represses these 
immune cells during aging and thereby reduces the natural ablation of senescent cells, aggravating 
loss of muscle mass observed during aging.
The myokines released by muscle cells not only signal to stem cells, but also attract 
immune cells that can facilitate tissue repair and regulate immune cell function. IL-15 is 
released by muscle cells in response to exercise and promotes survival of NK cells [37, 
38]; in contrast, NK cells are inhibited by IL-6 and TNFα [39]. An age-related decrease 
in muscle mass could therefore lead to a decrease in IL-15 and thereby a decrease 
in the number of NK cells, an effect aggravated by an increase in systemic IL-6 levels 
(Reviewed in [40]). Importantly, NK cells are natural eliminators of senescent cells [41]. 
Muscle atrophy during aging thus adds to the build-up of senescence by reducing the 
ability of the immune system to clear senescent cells. This, in turn, further accelerates 
muscle loss and age-related frailty. Studies are underway to determine whether anti-
senescence treatment can overcome muscle loss.
Aging is the greatest risk factor for most chronic diseases, and mechanistic 
links between aging and disease are starting to emerge. Several studies show an 
involvement of cellular senescence, and in particular, muscle stem cell senescence, 
in distinct types of muscular dystrophies. In Myotonic dystrophy type 1 (DM1 or 
Steinert’s disease), entry into senescence of human satellite cell-derived myoblasts 
Voorbereid document - Marjolein Baar.indd   84 17-04-19   17:20
85
Musculoskeletal senescence 
correlates with a lower proliferative rate than age-matched controls and has been 
causally implicated in the progressive atrophy and degeneration of DM1 muscles 
[22, 23]. Similarly, cellular senescence traits have been described in mdx mice, a 
widely used model of Duchenne muscular dystrophy (DMD), correlating with poor 
regenerative capacity [24, 25, 42]. Premature cellular senescence also underlies 
myopathy in a mouse model of limb-girdle muscular dystrophy [43]. Whether 
interference in cellular senescence can provide a therapeutic approach for these 
muscle diseases is unknown.
Bone: senescence distorts the balance between resorption and formation
During aging, there is an increase in senescence in the bone. This, in turn, can lead 
to changes in bone density. Bone consists of multiple cell types, including osteoblasts 
that form bone, osteoclasts that break down bone tissue, and osteocytes that make 
up the majority of bone cells (reviewed in [44]). Out of the various cell types that are 
affected, the main SASP producing cells are senescent osteocytes [45]. Osteocytes 
are known to influence osteoblast and osteoclast function [46], and SASP factors 
secreted by osteocytes, such as IL-1 and MMP13, increase osteoclast differentiation 
and thereby increase bone resorption to cause the age-related bone loss associated 
with osteoporosis [47-49]. The conditioned medium of senescent cells can decrease 
osteoblast function in vitro and promote osteoclast activity [50]. Furthermore, inhibition 
of senescence induction stimulates osteogenesis and prevents osteoporosis [51]. These 
observations indicate a causal role of senescence in disrupting the balance between 
bone formation and resorption, leading to osteoporosis. 
There are several mouse models that show accelerated aging and are known 
to have an increased number of senescent cells, such as mice with DNA repair or 
telomerase deficiency; such mice often show osteoporosis and other musculoskeletal 
afflictions [60, 61]. They are therefore ideal model organisms for studying the effect of 
senescence in these disorders. For example, Klotho-deficient mice show accelerated 
senescence and a wide variety of age-related diseases, including osteoporosis. When 
these mice were crossed with p16ink4a knockout mice, osteoporosis was attenuated 
[61], indicating that senescent cell ablation can potentially prevent this deterioration. 
Indeed, osteoporosis was delayed in naturally aged INK-ATTAC mice when senescent 
cells, which continuously develop, were ablated twice a week. Moreover, these mice 
had an improved microarchitecture and strength [62]. The reduction of senescent 
cells likely leads to a lower level of inflammation in the bone. This then reduces the 
formation of osteoclasts and prevents bone degradation. Indeed, in INK-ATTAC mice, 
bone resorption was lowered and bone formation improved. In conclusion, senescent 
cell removal prevents age-related bone loss in mice.
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In aged bone, the balance between bone formation by osteoblasts and bone resorption by 
osteoclasts is distorted. An accumulation of senescent cells is observed that promote an increased 
osteoclast activation through the SASP. Bone loss is also worsened by the inhibition of osteoblast 
formation by pro-inflammatory factors. For example, known SASP factors cause mesenchymal 
stem cells to favor adipogenesis over osteoblast production.
Bone stem cell function during aging is likely influenced by secreted SASP factors. 
Osteoblasts have a relatively short lifespan and are derived from mesenchymal stem 
cells in the bone marrow (BMSCs), periosteum and elsewhere [52]. BMSCs can give 
rise to both osteoblasts and adipocytes [53]. This balance is heavily influenced by the 
microenvironment [54], and during osteoporosis oxidative stress and inflammatory 
cytokines influence BMSCs to favor adipogenesis over osteogenesis [55, 56]. 
Therefore adipose tissue accumulation is a hallmark of osteoporosis and is linked 
to senescence in the microenvironment. Furthermore, BMSCs show a reduced 
differentiation capacity during aging. For example, serum from aged individuals 
inhibits differentiation of BMSCs into osteoblasts [57]. Additionally, BMSCs can 
become senescent during aging, secreting SASP proteins and promoting osteoclast 
activity [58, 59]. Overall, these observations indicate that targeting senescent cells 
in bone would likely improve bone stem cell function.
Cartilage: senescence-associated chronic inflammation perturbs cartilage 
regeneration
Articular cartilage – a flexible connective tissue that protects the ends of 
bones within a joint – affords smooth surfaces with low friction for movement, and 
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facilitates transmission of loads to the underlying bone. This tissue mainly consists 
of extracellular matrix produced by chondrocytes, the cell type present in cartilage. 
The regenerative potential of cartilage after damage is limited, possibly because 
the tissue contains a low number of mesenchymal stem cells [63]. Furthermore, like 
muscle stem cells, these stem cells are less able to regenerate damaged tissue with 
age. This is in part due to intrinsic MSC aging and senescence induction [64, 65], 
but is also due to the altered tissue microenvironment and chronic inflammation [66]. 
Additionally, chondrocytes can express stemness markers in osteoarthritis [67, 68]. 
Again, inflammatory factors promote a chronic dedifferentiated state and thereby 
prevent tissue repair during aging [69]. Altogether, this leads to thinning of cartilage 
during aging, resulting in stiffness and pain in the joints that are characteristic of 
osteoarthritis [70]. Figuur 3 ergens hier
A causal role of senescence in osteoarthritis was shown by transplanting 
senescent cells into mouse joints, resulting in pain and morphological changes 
indicative of osteoarthritis [71].
Age-related cartilage degeneration leads to osteoarthritis. Senescent chondrocytes present in 
aged cartilage cannot proliferate to regenerate damaged cartilage and induce extracellular matrix 
degeneration through the SASP. Furthermore, cartilage regeneration is inhibited during aging due 
to senescent mesenchymal stem cells.
Furthermore, chondrocytes show an age-related increase in senescence, 
and during osteoarthritis pro-inflammatory cytokines such as the prominent 
SASP factor IL-1 induce excess expression of matrix metalloproteinases (MMPs), 
leading to cartilage loss [72]. Increased levels of circulating SASP factors such 
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as IL-6 are linked to frailty and risk of osteoarthritis [73]. Additionally, in a mouse 
model of osteoarthritis, overexpression of SIRT6 prevents senescence induction 
and concurrent inflammation, thereby reducing cartilage degeneration [74]. This 
finding indicates that eliminating senescent cells from cartilage would attenuate 
osteoarthritis and improve joint function, especially since chondrocyte death does 
not seem to drive cartilage damage in response to injury [75]. Several studies have 
examined the effect of senescent cell removal on osteoarthritis development. For 
example, osteoarthritis was surgically induced in mice through anterior cruciate 
ligament transection (ACLT) in the knee joint. In this model, genetic removal of 
senescent cells delayed the development of osteoarthritis, evidenced by reduced 
inflammation in the knee joint and an increase in cartilage development, indicating 
better joint function [76]. The mice had less pain after the senescent cells were 
removed. Furthermore, osteoarthritis occurs naturally in aged INK-ATTAC mice, and 
cartilage degeneration was attenuated after removal of senescent cells in this model.
Targeting senescence to counteract age-related frailty
The encouraging results obtained upon genetic elimination of senescent cells 
have important implications for the treatment of musculoskeletal deterioration. 
Since senescence is thought to play a significant role in the progression of age-
related frailty, anti-senescence drugs can be predicted to benefit patients with 
musculoskeletal disorders. 
Effects of senescent cell removal on the musculoskeletal system
Currently, drugs that target inflammatory cytokines are tested in patients with 
musculoskeletal diseases. For example, several strategies for IL1 inhibition in 
osteoarthritis have been explored. These therapies include IL1 receptor antagonist 
proteins (IRAP), monoclonal antibodies targeting free IL1 or the IL1-receptor, and an 
inhibitor of IL1β production called Diacerein (reviewed in [77]). Most of these therapies 
show a trend of pain reduction versus placebo. However, these results were often not 
statistically significant, possibly due to the short half-life of the antagonist proteins or 
blocking antibodies. Only Diacerein treatment has shown significant anti-inflammatory 
effects and pain reduction in most studies [77]. Treatment of mdx dystrophic mice 
with the NAD+ precursor nicotinamide riboside (NR) prevented senescence of muscle 
stem cells, and this rejuvenated their regenerative capacity [24]. The Notch pathway 
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is chronically activated in severely dystrophic muscles of mdx mice double mutant 
for dystrophin and utrophin, and blocking this pathway with the γ-Secretase inhibitor 
DAPT reduced stem cell senescence and the histopathological features of DMD 
[42]. Importantly, abolition of p16INK4a, which accumulates abnormally in satellite cells 
of DM1 muscles, partially restores early growth arrest and reduces senescence in 
vitro [22], reinforcing the idea that this mechanism might participate in the impaired 
regeneration of DM1 muscles. Notably, the regenerative deficit of satellite cells from 
dystrophic muscles resembles that of geriatric mice, which also show p16INK4a-induced 
senescence and can be rejuvenated by silencing of the gene encoding p16INK4a [21]. 
Overall, these studies show limited effects, and the long-term safety of these drugs 
and/or genetic approaches has yet to be assessed. However, it is unlikely that essential 
molecules and pathways such as Notch or p16INK4a can be targeted systemically without 
severe secondary effects. In addition, these strategies are aimed at reducing symptoms 
and do not treat the underlying causes of disease progression. Removal of senescent 
cells is expected to reduce these inflammatory proteins while preserving stem cell 
function and is therefore expected to be safer and have more long-lasting effects.
The results obtained after genetic removal of senescent cells prompted a search 
for therapeutically applicable anti-senescence compounds. A small number of these 
compounds have been discovered, with varying degrees of success. One example 
is Navitoclax, a BCL2 family inhibitor. In the musculoskeletal system, Navitoclax 
was found to decrease the expression of cytokines that promote osteoclast activity 
in vitro, such as IL‐1α and MMP‐13 [58]. Furthermore, muscle stem cells isolated 
from naturally aged, Navitoclax-treated mice showed improved clonogenicity [78].
A major challenge when developing anti-senescence therapies is to avoid 
toxicity to healthy non-senescent cells. It is therefore important to identify the unique 
characteristics of senescent cells that can be targeted by a therapeutic compound. 
Senescent cells often express persistent nuclear damage foci called DNA-SCARS 
(DNA Segments with Chromatin Alterations Reinforcing Senescence) that contain DDR 
proteins such as 53BP1, γH2AX and activated p53[79]. These DNA-SCARS play a 
role in maintaining permanent growth arrest and are critical for SASP expression. In 
addition, we recently showed that the transcription factor FOXO4 resides within PML 
bodies fused to these persistent damage foci[19]. Here, FOXO4 binds p53 and prevents 
p53-dependent apoptosis. In order to disrupt this interaction and to induce apoptosis, 
we prospectively generated a D-Retro-Inverso peptide mimicking the FOXO4 p53-
binding domain. This peptide, FOXO4-DRI, causes the release of p53 to the cytoplasm, 
where p53 indeed induces apoptosis in a transcription independent manner. Indeed, 
in vivo use of FOXO4-DRI shows promising results. For these experiments we made 
use of XpdTTD/TTD mice that show accelerated aging and age-related ailments such 
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as osteoporosis and are therefore an ideal model for musculoskeletal diseases [60]. 
FOXO4-DRI treatment improved overall fitness and renal function in these mice, 
including an improved running wheel performance[19], an especially promising result 
for the treatment of musculoskeletal diseases. FOXO4-DRI showed around 10 fold 
selectivity for eliminating senescent vs. control cells. While enough for experiments in 
rodents, translation to the clinic requires further improvement to eliminate toxicity, which 
would be intolerable in this setting. Such efforts are now underway in our laboratory.
Unanswered questions
As we highlighted here, the tissues of the musculoskeletal system are damaged by 
inflammation during aging. Cellular senescence, by driving a persistent inflammatory 
response, is a major contributor to these effects. However, it remains unclear which 
senescent cell types are the main producers of these pro-inflammatory factors. Aging 
of the musculoskeletal system is due to both local and systemic factors. For example, 
senescent cells transplanted into cartilage can independently cause osteoarthritis 
[71]. On the other hand, systemically increased IL-6 levels are linked to muscle 
wasting, and the immune system also seems to be crucial in this process [28, 29]. This 
systemic inflammation can be caused by many cell types. For example, adipose tissue 
significantly contributes to systemic inflammation [80]. Fat present in joints can produce 
factors that promote osteoarthritis [81]. In turn, cells of the musculoskeletal system also 
secrete systemic factors and influence overall tissue integrity. For example, muscle 
cells affect NK cells during aging and, as NK cells are responsible for clearance of 
senescent cells[41], these would also influence the systemic senescence burden. Since 
various anti-senescence compounds potentially kill distinct subsets of senescent cells, 
it is vital to know which cell type to target; knowledge about which senescent cells 
contribute most to musculoskeletal degeneration will ultimately guide the development 
of effective treatment. Anti-senescence therapy may also be beneficial for several 
incurable muscular dystrophies and for wasting, by reducing inflammaging and hence 
boosting the satellite cell regenerative functions. Interestingly, cellular senescence 
has been shown to mediate fibrotic pulmonary disease, and senescent cell ablation 
improves pulmonary function in this setting [82]. Most dystrophinopathies also feature 
increased muscle fibrosis [83], which aggravates disease progression by substituting 
muscle with scar tissue, and it is plausible that anti-senescence cocktails will also halt 
fibrosis and improve patient health status. Thus, elimination of senescent cells may 
have benefits for tissue repair by reversing several detrimental processes; however, it 
remains to be determined whether senescence should be blocked partially or totally or 
eliminated only once early potential stemness-related functions have been completed. 
The answers to these questions may not be easy to obtain, yet we are rapidly obtaining 
tools that allow manipulation of the senescence process (for removing senescent 
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cells, neutralizing the SASP, or both processes). The final goal is to preserve stem cell 
benefits while minimizing the deleterious consequences of senescence.
It also remains unclear how tissues rejuvenate after senescent cell ablation and 
whether side effects or unexpected challenges will occur. For example, in addition to 
its potential to eliminate senescent cells, tissue engineering is being explored as a 
treatment for musculoskeletal diseases. In this scenario, stem cells are isolated and 
healthy tissue is generated ex vivo to replace damaged tissues such as cartilage 
and bone. For example, mesenchymal stem cells can be isolated and cultured on a 
biodegradable scaffold where they are stimulated with TGFβ to induce differentiation 
into chondrocytes [84]. This newly formed cartilage could then be used for surgical 
reconstruction of joints. However, a major challenge in tissue engineering is to prevent 
stem cell senescence[85]. It remains unclear whether similar issues will arise after 
senescence clearance. So far, tissue regeneration seems efficient after these cells 
are removed. For example, although cartilage has a weak regenerative potential, 
it is rejuvenated after senescent cells are removed. Tissue-specific stem cells are 
likely key to this regeneration. It is possible that the reduction of SASP proteins in 
the tissue microenvironment releases these cells from their ‘stem cell lock’, resulting 
in a restored regenerative potential. In addition, cells that are dedifferentiated due to 
senescence, such as chondrocytes, could help rejuvenate musculoskeletal tissue. In 
general, multiple factors likely contribute to this rejuvenation. Both local and systemic 
inflammation are expected to decline, affecting immune system functioning, natural 
senescent cell clearance, stem cell function, and tissue regeneration.
In conclusion, targeting senescence has the potential to prevent or reverse 
multiple age-related diseases and to reduce frailty. Furthermore, it seems likely that 
therapeutically applicable anti-senescence compounds will be available in the future. 
However, the toxicity of these drugs remains a major concern. Periodic treatments 
will likely be necessary to maintain possible beneficial effects and it is still largely 
unknown what the effect of multiple treatment rounds will be. Therefore, the timing 
and frequency of these treatments should be studied, as well as the long-term effect 
of senescence clearance on biological processes such as stem cell function.
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“Targeting signs of aging”. It sounds more like a punch-line of a TV commercial, 
than a consequence of fundamental science. But as we observed recently, it 
might actually be possible to achieve just that, using a prospectively designed 
FOXO4-p53 interfering peptide that targets so-called “senescent” cells1. More 
research is needed to fully assess its true translational potential and whether it 
is even safe to remove such cells. However, these findings pose a very attractive 
starting point to develop ways to live out our final years in better health.
Aging has often been considered as an integral part of life; a form of “noise” that 
cannot be targeted or tampered with. This is in part because for long the underlying 
causes of organismal aging were simply too elusive to comprehend, let alone modify. 
The chronic build-up of DNA damage has now evidently been established as a major 
cause for aging, but to counteract the genomic damage that has occurred over a 
lifetime is an entirely different challenge altogether2. One approach to overcome 
this issue, is to eliminate those cells that are too damaged to faithfully perform their 
duty and to replace them by fresh and healthy counterparts. Senescent cells are 
exciting candidates for such an approach. Comparable to formation of rust on old 
equipment, like a bicycle (Fig. 1), they accumulate during aging and especially at sites 
of pathology. They develop a chronic secretory profile that is thought to impair tissue 
renewal and contribute to disease development, for instance by keeping neighboring 
cells “locked” in a permanent state of stemness2. Senescence can be beneficial in a 
transient setting, but the genetic removal of senescent cells over a prolonged period 
of time was found to be safe and to potently extended health- and lifespan of naturally 
aging mice3. Thus, senescence is an irrefutable cause for aging and targeting them 
is warranted. But can they also be eliminated therapeutically? And are such methods 
then safe on their own? And last, but not least, would such methods be applicable 
to not merely delay, but also to reverse aging?
Le tour de FOXO. A demanding journey, but one with great rewards.
A first surprise when trying to address these questions was that senescent 
cells recruit a factor called FOXO4 to sites of persistent DNA damage, structures 
absent in normal healthy cells1. This is intriguing as FOXO4 is considered to be 
the ugly little sister of FOXO1 and FOXO3, which do play major roles in processes 
ranging from stem cell function, differentiation, tumor suppression, and, aging4. In 
senescence, however, FOXO4 appears to act as a brake on the apoptosis response 
by sequestering p53. Prospective design of a D-Retro-Inversed Cell Penetrating 
Peptide that perturbs this interaction, named FOXO4-DRI, allowed for nuclear 
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release of active p53, followed by cell-intrinsic apoptosis and selective elimination 
of the senescent cells.
Recent work elegantly proved that senescent cells are a major cause for the toxic 
side effects caused by multiple independent forms of chemotherapy5. Excitingly, 
FOXO4-DRI counteracted senescence caused by Doxorubicin and reversed liver 
toxicity providing evidence that therapeutic removal of senescent cells by FOXO4-
DRI can counteract at least some aspects of chemotoxicity. Proceeding from this 
acute senescence-induction model, we then focused on fast aging XpdTTD/TTD mice, 
which spontaneously develop senescence in an accelerated fashion, in parallel 
with organism-wide deterioration. FOXO4-DRI proved to significantly restore their 
health on multiple levels. Though not purposefully investigated, it was strikingly 
apparent that FOXO4-DRI treated mice regained fur and improved their voluntary 
exploratory behavior compared to PBS treated counterparts. In addition, kidney 
function markedly restored. Naturally aged mice showed more biological noise than 
the fast aging mice, making these features more difficult to address. But at least the 
effects on renal function were clearly prevalent in naturally aged mice. Thus, using 
FOXO4-DRI it indeed appears possible to not just delay aging but also reverse at 
least certain signs of it. So, what’s next?
A combination of efforts to best the mountains ahead
Aging is ultimately still inevitable. But perhaps it can be strongly postponed, or 
even reversed, when independent anti-aging therapies are combined? It remains 
to be determined whether extension of lifespan is possible in humans6, let alone 
whether this is desirable and then to what age? After all, life could at some point 
not simply “complete”? While this might be true for some, nobody likes being sick 
and frail. Imagine the possibilities if we would be able to enjoy our time with loved 
ones, exercise and travel more and simply just enjoy life in good health, instead of 
spending it in a retirement home.
Extending the healthy years of life is now closer than ever, but we are still not 
there yet. While mechanics can remove defective parts from an old bicycle, it is far 
more challenging to remove damaged parts from an old body (Fig. 1). Anti-aging 
strategies have therefore necessarily focused thus far on stalling the inevitable for as 
long as possible by eating less and exercising more. A multitude of new diets make 
it to the mainstream public each year, but ironically, people tend to exercise less 
and gain more and more weight. This argues that instead of focusing so much on 
dietary interventions, independent approaches deserve to be investigated. Here, we 
underscored the potential of therapeutic elimination of senescent cells, for instance 
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by FOXO4-DRI. In addition, exciting developments were recently reported in the fi eld 
of stem cell biology, where it was shown that transient expression of the Yamanaka 
stem cell factors can promote tissue rejuvenation7. This is not yet therapeutically 
applicable, but this will most likely only be a matter of time.
It is no longer merely science-fi ction to restore healthspan with rationally designed 
approaches. To fully achieve the best possible outcome, it will therefore deserve special 
consideration to combine existing methods to delay aging with the recently developed 
therapies that counter senescence and promote tissue rejuvenation. With these, we 
fi nally have exciting tools to maintain and repair the aging cycle of life (Fig. 1). Time to 
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The aging cycle of life. The analogy compares senescent cells in an aged body to rust on a racing 
bicycle. Different strategies can be used to prevent, treat and remove rust and aging. WD-40, a 
corrosion inhibitor, resembles dietary restriction and regular exercise to delay rust or aging. When 
rust and aging have already settled, the FOXO4-DRI peptide can act as a rust remover by inducing 
cell death in senescent cells. Last, the stimulation of tissue rejuvenation can promote a healthy, 
revitalized tissue that can be compared with the replacement of bicycle parts. The combination of 
these strategies may be complimentary in fi ghting aging and age-related defects.
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